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Chemicals policy is designed to protect human and ecological health from the adverse effects 
that can result from exposure to manufactured chemical substances. It entails a complex 
process of regulatory chemical risk assessment and risk-management decision-making, 
drawing expertise from a diverse range of fields including toxicology and environmental 
health. However, these decision-making processes have come under increased scrutiny in 
recent years – criticized for bias, lack of transparency, rigor and a failure to identify 
unacceptable risks before widespread exposure occurs. This has resulted in calls for a more 
“evidence-based” approach, in which all relevant, available evidence is analyzed in a robust, 
transparent and reproducible manner. There is thus a growing need to incorporate 
methodological frameworks capable of facilitating evidence-based approaches to chemical 
risk assessment and regulatory decision-making.  
Such frameworks have been successfully developed in the field of medicine, which underwent 
a similar paradigm shift to that currently shaping chemical risk assessment, in the early 1990s. 
The gold-standard for evidence-based decision-making championed by the evidence-based 
medicine movement takes the form of systematic review. Systematic review describes a 
prescriptive and transparent method for collating, appraising and analyzing all available, 
relevant evidence in answer to a specific research question. By pooling the results of individual 
(independent) studies, systematic reviews synthesize conclusions which are not only more 
precise but are representative of an entire evidence-base. Now well established within clinical 
decision-making, the application of systematic review to chemical risk assessment is beginning 
to gain prominence.  
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However, several challenges and barriers threaten to slow the uptake and quality of 
systematic review for chemical risk assessment. These include the prohibitively narrow focus 
of systematic reviews, which are at odds with the information requirements of regulatory 
decisions, and a mismatch in the resource availability within chemical risk assessment 
compared to the resource demands associated with systematic review.  
This thesis explores the challenges associated with implementing evidence-based approaches 
such as systematic review for chemical risk assessment, and identifies key methodological 
solutions: 
Chapter 1 examines the risk of bias assessment process – one of the most important but also 
most challenging aspects of systematic review methodology to adapt for environmental 
health. It examines the rationale for eschewing seemingly objective, quantitative approaches 
to assessing risk of bias in favour of seemingly more subjective, qualitative approaches. 
Through illustrative models, this thesis uncovers the mismatch between the mechanics of 
quantitative risk of bias assessment methods and the fundamental mechanics of risk of bias 
itself. Promoting understanding of this issue is increasingly important as systematic review 
gains prominence within chemical risk assessment – a field traditionally reliant on quantitative 
scoring methods for assessing the quality of included evidence.  
Chapter 2 considers the wider challenges to uptake of systematic review in environmental 
health, and proposes “systematic evidence mapping” as a methodological solution. A 
systematic evidence map is a queryable database of systematically gathered evidence which 
facilitates the broader identification of trends across the evidence-base. In this thesis, the 
potential utility of systematic mapping for existing and future chemical risk assessment 
workflows is characterized and critically assessed. A hypothetical but representative example 
(in which legacy flame retardants are prioritized for further regulatory assessment) is used to 
demonstrate the trend-spotting capacity of the methodology. 
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Chapter 3 further explores the methodological adaptions required for effective 
implementation of systematic evidence mapping in chemical risk assessment and wider 
environmental health. By surveying current evidence mapping practice in environmental-
management (a field where the methodology is more mature), and qualitatively appraising 
this practice against the concepts of “data storage technology”, “data integrity”, “data 
accessibility”, and “transparency”, this thesis reveals the ill-suited nature of conventional 
tabular data structures for housing complex and highly connected environmental 
health/toxicology data.  It identifies graph-based storage technologies as the most flexible and 
optimally suited data structures for the varied needs of chemical risk assessment workflows, 
and makes recommendations for their uptake in systematic evidence mapping. 
Chapter 4 of this thesis explores the practical implementation of graph-based solutions to 
evidence mapping in environmental health by conducting a proof-of-concept evidence 
mapping exercise, in which trends in the study of exposure-outcome associations for National 
Health and Nutrition Examination Survey (NHANES) datasets in the academic literature are 
explored. By contrasting this graph-based evidence mapping exercise to an equivalent tabular 
scoping review, this chapter demonstrates how significant gains in resolution and complexity 
can be achieved by adopting the graph data model – leading to greater insights than can be 
offered by traditional evidence-surveillance methods. The transparency, accessibility, 
interoperability and potential to expand graph-based evidence maps is also highlighted in this 
chapter by providing data models and methods which can be further adapted e.g. for the 
development of a suitable controlled vocabulary ontology.   
Finally, this thesis concludes by discussing the future direction of evidence-based chemical risk 
assessment and the role of graph-based evidence mapping within it, highlighting the need for 
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Chemicals regulation, risk assessment and risk-management   
Manufactured chemicals are ubiquitous to all aspects of modern life. Designed to perform a 
range of functions, they are integral to the consumer goods and industrial processes on which 
society relies. The chemicals industry is beneficial for improving standards of living and life 
expectancy, as well as promoting economic growth. However, many of its products can 
additionally have unintended and/or unforeseen negative impacts on human and 
environmental health (Egeghy et al., 2012; Koch & Ashford, 2006; Schwarzman & Wilson, 
2009). It is therefore vital to implement a system able to identify, weigh and control the risk 
of such adverse outcomes. This function is served by the chemicals regulation system, which 
promotes maximum benefit of manufactured chemicals by minimising the harmful 
consequences of their use, driving industry towards safer alternatives.  
Chemicals regulation achieves these aims by setting limits that control a population’s exposure 
to a chemical through restricting its manufacture, distribution and disposal or controlling its 
approved uses. In the European Union (EU), the European Chemicals Agency (ECHA) 
implements such legislation through the REACH regulation (Registration, Evaluation, 
Authorisation and Restriction of Chemicals).  
The severity of regulatory action taken against a chemical substance is determined by 
assessing the risk associated with exposure to that substance. 
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Chemical risk assessment is a complex process comprised of four key stages (Beronius & 
Vandenberg, 2015; National Academy of Sciences, 1983):  
 
• hazard identification - assessing the hazardous properties intrinsic to a chemical; 
• hazard characterisation – charactering the relationship between chemical dose and 
biological response, i.e. investigating the mode and level of exposure required for 
the substance’s hazardous properties to affect an adverse outcome; 
• exposure assessment - investigating and/or estimating the potential sources and 
severity of a population’s exposure to a chemical; 
• Risk characterisation – combining hazard and exposure data to determine the 
magnitude of the risk posed by a chemical substance. 
A variety of heterogeneous data sources are relevant to each of these stages, encompassing 
physio-chemical, in-vitro, in-vivo, in-silico and human epidemiological studies, as well as 
environmental- or bio-monitoring and exposure studies. Chemical risk assessment, and the 
subsequent risk-management process, draw together these varied scientific disciplines when 
reaching overall conclusions on the safety of a chemical substance. It is the challenges 
associated with drawing together, managing and synthesising data from disparate sources, 
and the consequences of failing to meet those challenges, which motivate the research 
discussed in this thesis.  
Regulatory failings, data availability and regulatory reform  
Chemicals regulation is designed to protect human and environmental health (Abelkop & 
Graham, 2014). However, regulatory decisions have not always been successful in meeting 
this aim. Chemical policy’s brief history is marred by case studies of regulatory failure, where 
substances allowed to market are later confirmed to be of significant harm to public and/or 
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environmental health (Commission of the European Communities, 2001; European 
Environment Agency, 2013). The adverse effects which result from such widespread exposures 
can be severe, irreversible but also long-lasting – as persistent and/or bio-accumulative 
substances continue to cause harm many years after reactive regulatory action reduces or 
eliminates sources of exposure. This is well illustrated by case studies concerning exposures 
to infamous legacy chemicals such as dichlorodiphenyltrichloroethane (DDT) (Commission of 
the European Communities, 2001) and polychlorinated biphenyls (PCBs) (Silbergeld et al., 
2015).  
Consequently, regulatory frameworks and the chemical risk assessment process have come 
under increased scrutiny in recent times (Whaley et al., 2016). Lack of sufficient toxicological 
data, and failure to adopt a precautionary approach in light of such data gaps, have been cited 
as key flaws of regulatory frameworks (Applegate, 2008; Eckley & Selin, 2004). In a 1998 report 
by the US EPA, it was estimated that a full set of basic toxicity data was only available for 7% 
of the high production volume chemicals (produced or imported at or above 1 million pounds 
per year) produced in the US – with 43% of those chemicals lacking any human or 
environmental toxicity data at all (EPA’s Office of Pollution Prevention and Toxics, 1998). 
Similarly, in a white paper published by the European Commission, it was indicated that some 
80,000 legacy chemicals (released to market prior to 1981) in use across Europe had 
undergone no formal risk assessment (Brown, 2003; Commission of the European 
Communities, 1998, 2001).  
These issues are being addressed by initiatives to reform reactive chemicals regulation 
systems  toward more proactive systems, where the risks associated with exposure to 
chemical substances can be assessed and managed prior to their release (Abelkop & Graham, 
2014; Commission of the European Communities, 2001; United States Environmental 
Protection Agency, 2016).  
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The largest, most ambitious and complex of these reforms is that of the European Union’s 
REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) regulation 
(Commission of the European Communities, 2001; European Comission, 2016).  In contrast to 
the frameworks which it replaces, REACH operates under a “no data, no market” ethos 
(European Comission, 2016). It shifts the burden of demonstrating safety away from regulators 
and onto manufacturers. Entered into force in June 2007, REACH has seen data gaps for tens 
of thousands of chemicals filled within its 10 year registration period (ECHA, 2019a). While not 
as extensive as REACH, the recent reform of the US Toxic Substances Control Act (TSCA) has 
similarly introduced measures designed to fill data gaps (Schmidt, 2016; United States 
Environmental Protection Agency, 2016). 
However, with so many legacy chemicals in commerce (Abelkop & Graham, 2014), and with 
new chemicals continually approaching market, filling data gaps represents a considerably 
resource intensive task. A key feature of REACH designed to avoid redundant repeat toxicity 
testing is the requirement that applicants registering a chemical substance share toxicity data 
with other manufacturers of that substance. This data is made available in the International 
Uniform Chemical Information Database (IUCLID), which has been described as the “world’s 
largest database on the properties of chemical substances” (Buxton, 2017; European 
Comission, 2016).  
To further improve resource efficiency and the minimisation of expensive and/or unethical in-
vivo toxicity testing, REACH and other reformed chemicals policy workflows emphasise the 
need to identify, and make best use of, pre-existing data. For example, pre-existing data can 
be used within REACH in read-across applications, where predictions regarding the 
toxicological behaviour of data-poor substances can be made by evaluating structurally similar 
data-rich substances (Schaafsma et al., 2009; Vink et al. 2010); or in  weight-of-evidence 
assessments (WoE) – where, although data for a specific toxicological endpoint may be 
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insufficient, the data gap can be addressed by combining related data from several 
independent pre-existing sources (ECHA, 2019b; Schoeters, 2010). 
Continued discrepancies in chemical risk assessment 
In tackling the toxicity data gap, reformed regulatory processes such as REACH serve to 
demonstrate how lack of data is a solvable and diminishing challenge for chemicals policy. 
Despite this, concerns over the generation, identification and/or synthesis of toxicologically 
relevant data continue to be raised (Hartung, 2009; Hoffmann & Hartung, 2006). 
Consequently, the chemical risk assessment process has been criticised for issues concerning 
conflicts of interest, poor transparency (Ingre-Khans et al., 2016), poor reproducibility and a 
continuing tendency to miss “early-warnings” (European Environment Agency, 2013;  
Hoffmann & Hartung, 2006). These concerns are in-part founded by the fact that while more 
data is available for chemical risk assessment (i.e. endpoints for a larger suite of toxicological, 
chemical and exposure testing) the frameworks for collecting, managing and appraising this 
data remain unsystematic and opaque. This is a key criticism of the current REACH registration 
and assessment frameworks (Ingre-Khans et al., 2016), whereby the methods used to collate 
and select the evidence presented in registration dossiers and chemical risk assessments are 
inaccessible.   
This makes it difficult to determine whether the data selected for chemical risk assessment is 
in fact representative of all available evidence, or whether this data has been cherry picked; 
potentially by an industry with vested interests in a substance’s regulatory approval (a threat 
of particular relevance to REACH (Ingre-Khans et al., 2016)). Appraising the assessment 
process itself, in which selected data are analysed and evaluated to reach conclusions on a 
chemical’s safety, is similarly difficult. This process has traditionally relied upon expert 
elicitation (Ingre-Khans et al., 2016; Morgan, 2014) – where a panel of specialists with varied 
expertise interpret primary toxicity and exposure data for the wider human or environmental 
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context. However, without an objective, consistent and robust framework to guide expert 
assessment, the conclusions of this process may be biased by the variation in methodological 
choices made by assessors, and by the variation in individual knowledge, experiences and 
opinions which exist from one expert to the next (Rudén, 2001b; Whaley et al., 2016).  
Several case studies demonstrate the discrepancies which can arise from an unsystematic and 
opaque chemical risk assessment process, where different assessors reach conflicting 
conclusions regarding a chemical’s safety despite access to the same evidence base (Hoffmann 
& Hartung, 2006; Whaley et al., 2016). Examples range from inconsistent and/or contradictory 
conclusions between two risk assessments (e.g. PCBs (Golden et al., 2003)) to multiple risk 
assessments (e.g. trichloroethylene, for which 29 assessments reached varied conclusions 
(Rudén, 2001b, 2001a)). Similarly, discrepant risk assessments lead to contradictory and 
conflicting regulatory action from one authority to the next (e.g. between European Food 
Safety Authority (EFSA) and the French Agency for Food (ANSES) regarding the regulation of 
Bisphenol-A (BPA) (Whaley et al., 2016)).  
Such discrepancy causes uncertainty, confusion and a lack of trust in the ability of chemicals 
policy to protect human and environmental health. Thus, robust, transparent and systematic 
methodological frameworks are required to ensure that chemical risk assessments avoid bias 
and discrepancy. At the very least, increased methodological rigour and transparency would 
allow sources of discrepancy to be identified and assessed by all stakeholders. Such 
methodological frameworks are offered by evidence-based approaches such as systematic 







Systematic review is a method of systematically gathering, appraising and synthesising all 
relevant and available evidence such that a single, representative answer to a specific research 
question can be derived from the pooled results of individual, independent studies.  
The steps of the methodology are organised within a consistent and prescriptive framework 
(summarised briefly in Figure 1 and elaborated further in Table 2 of Chapter 2). Each step 
advocates transparency, and is designed to ensure the rigour of the review and/or the 
representativeness of its pooled finding/s. Briefly, systematic review builds on the methods of 
traditional narrative reviews in several key ways (see Chapters 1 and 2 for further detailed 
discussion of systematic review methods):  
• All methodological decisions are planned ahead of commencing the review and are 
specified in a pre-published protocol. This holds reviewers accountable to their 
methods and prevents the kind of ad-hoc analyses which introduce bias and 
discrepancy. Pre-published protocols also increase transparency and reproducibility, 
allowing others to critically appraise the methods via which a review conclusion has 
been reached and to update the review in the future. Pre-publication of systematic 
review protocols also offers an opportunity for peer-review of planned methods, 
allowing any potential issues or sources of bias to be amended prior to conducting the 
review itself.  
• Systematic searches form the basis of the evidence gathering step of systematic 
reviews. A systematic search consists of a series of search strings formatted for specific 
bibliographic databases. These search strings are designed to cover all key concepts 
relevant to the review question and ensure that the search returns as much relevant 
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information as is available. Reporting the search strategy (i.e. the combination of 
search strings and bibliographic databases searched) in the review’s protocol ensures 
the search can be updated in the future.  
• In contrast to narrative reviews, which rely on ad-hoc processes of literature searching 
and selection, often shaped by the reviewer’s own expertise and interests – systematic 
reviews ensure that the all search results returned via a systematic search are 
considered for inclusion in the review (against a set of pre-defined inclusion criteria). 
Giving equal consideration to all returned results ensures that no potentially relevant 
information is omitted from the review.   
• Assessing the risk that studies included in a systematic review are biased is a key 
feature of systematic review methodology (see Chapter 1) – which aims to consider 
the potential impacts that this bias might have on the results of the review.  
• In contrast to narrative reviews – which may have a broader focus or may not be 
driven by a narrowly focused research question e.g. instead describing the “state of 
the science” within a field– systematic reviews address specific, closed-framed 
research questions. They employ narrative or statistical methods (as appropriate) for 
deriving an overall answer to this research-question.  
• Many of the steps of the systematic review process are conducted in duplicate by at 
least two independent reviewers, including the literature screening, data extraction 
and risk of bias assessment processes. This ensures the rigour of the review process 





Figure 1: Brief outline of the methodological stages involved in conducting a systematic 
review. All proposed methods are clearly defined in a pre-published protocol, holding 
reviewers accountable to their methods and creating an opportunity for peer-review and 
stake-holder input. Several stages of the review process are conducted in duplicate by two 
independent reviewers – minimizing the influence of human error and ensuring consistent 
understanding of the research methods and objectives.  
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The origins of systematic review methodology lie in the field of medicine, where it was 
introduced as a tool for clinical decision-making. It arose out of the evidence-based medicine 
(EBM) movement in the early 1990s (Chalmers et al., 2002; Hooker, 1997), which sought to 
shift the paradigm of clinical-decision making away from its reliance on expert opinion, 
experience and intuition, and toward the more holistic consideration of best current available 
evidence (Guyatt et al., 1992). As well as increasing the robustness and precision of clinical 
decisions, the introduction of systematic review sought to increase transparency and 
accountability within a field plagued by discrepancy and bias (Goldacre, 2013). It has since 
become firmly established in the field, with organisations such as the Cochrane Collaboration 
(The Cochrane Collaboration, 2019) leading the production of accessible high-quality 
systematic reviews, methodological guidance and standards (Lefebvre, 1994).  
The similarity between the issues faced in clinical decision-making and chemicals policy 
settings, and the demonstrable success of systematic review in overcoming these issues in the 
field of medicine have led to increasing interest in the application of systematic review to 
chemicals policy contexts such as chemical risk assessment (Whaley et al., 2016). Calls for a 
move toward evidence-based toxicology (EBT) (Hoffmann & Hartung, 2006) have seen 
systematic reviews on environmental health topics begin to emerge (Whaley & Halsall, 2016) 
along with networks and collaborative workgroups (e.g. (Johns Hopkins Bloomberg School of 
Public Health, 2019; NTP-OHAT, 2019; The Endocrine Disruption Exchange, 2019b; UCSF 
Program on Reproductive Health and the Environment, 2019)) dedicated to establishing the 
methodology within the field. While regulatory agencies such as ECHA are yet to incorporate 
systematic review in their assessment frameworks, the US EPA have recently taken up the 
methodology for TSCA risk evaluations (EPA, 2018).  
Although increasing interest in systematic review is indicative of progress within the EBT 
movement, evidence-based methods are still relatively novel to the field and several barriers 
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to their effective adaptation and widespread uptake remain. In clinical settings, evidence 
synthesised in a systematic review is typically derived from studies of similar design (i.e. 
randomised controlled trials) in answer to a well-defined research question (e.g. Is x an 
effective treatment for y in population z?). However, evidence from a heterogenous range of 
study designs must be integrated when addressing research questions regarding chemical risk 
assessment. The focus of those questions is also more complex to define for chemical risk 
assessment where no measure of a single, consistent outcome is necessarily indicative or 
sufficiently informative of toxicity in the same way as the prevalence of a single, consistent 
outcome might be indicative of an effective clinical treatment. 
Despite methodological guidance for addressing these and other challenges specific to 
environmental health systematic reviews (Hoffmann et al., 2017; NTP, 2015; Woodruff & 
Sutton, 2014), examples of questionable methodological conduct continue to emerge (Whaley 
& Halsall, 2016).  Similarly, despite the growing presence and application of systematic review 
in chemical risk assessment contexts, ECHA have yet to follow the US EPA in adopting the 
methodology. This indicates a need for further research into the successful implementation of 
evidence-based methodologies in environmental health, as well as the need to disseminate 
such research to stakeholders working within a chemical risk assessment capacity – including 
regulatory bodies such as ECHA and the US EPA. It is this need which motivates the research 
discussed in this thesis.  
 
Aims and structure of this thesis  
This thesis aims to explore the adaptation and application of evidence-based methods for 
chemical risk assessment and risk management decision-making within chemicals policy and 
wider environmental health. This overarching aim is met through four key objectives. These 
objectives, and the chapters in which they are addressed, are briefly summarised below. 
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Finally, this thesis concludes by outlining the future work required to successfully implement 
evidence-based approaches to chemical risk assessment at scale.  
Objective 1: Understand the challenges associated with implementing systematic 
review in chemical risk assessment and wider environmental health. 
Chapter 1 of this thesis focuses on a significant challenge for systematic review: the use of 
quantitative systems for assessing risk of bias in included studies. Assessing the risk that 
studies included in a systematic review are biased is a key step of the systematic review 
process (Fig. 1) and determines the degree to which the conclusions of a systematic review 
can be trusted. The Cochrane Collaboration advises against the use of quantitative, scoring-
based systems for assessing risk of bias in included studies, and offers an alternative, 
qualitative “domain-based” approach (Higgins, 2011). Despite this advice, quantitative 
scoring-systems have become a prevalent issue in the field of medicine.  
 
As with the Cochrane Collaboration, there is an understanding of these issues among the 
workgroups dedicated to establishing systematic review in environmental health. Guidance 
published by The National Toxicology Program’s Office for Health Assessment and Translation 
(NTP-OHAT) (OHAT, 2015) and the Navigation Guide (Woodruff & Sutton, 2014) both advise 
against the use of quantitative scoring systems and instead offer guidance for making 
qualitative, domain-based risk of bias assessments. However, as in the field of medicine, the 
allure of quantitative scoring systems for assessing risk of bias threaten the robustness and 
transparency of systematic review practice in environmental health – especially while the 
methodology and its associated best-practice are still relatively novel to the field. This can be 
evidenced by the fact that, despite methodological guidance advocating otherwise, the 
systematic review methodology adopted by the US EPA for TSCA risk evaluations uses a 
numeric scoring system for risk of bias assessment (EPA, 2018). Similarly, the critical appraisal 
process associated with chemical risk assessments conducted under REACH adopt the Klimisch 
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criteria (Klimisch et al., 1997) – a quality scale in which studies are rated using numeric 
judgements. Chapter 1 addresses the issue of quantitatively assessing risk of bias of included 
studies. It aims to improve understanding of systematic review methodology (and its 
motivating rationale) within environmental health – learning from the challenges encountered 
in the field of medicine and warning against their introduction to chemical risk assessment.  
 
However, there are several additional challenges associated with the implementation of 
systematic review which are more specific to chemical risk assessment. These challenges stem 
from the higher degree of heterogeneity present in studies relevant to chemical risk 
assessment, as well as the breadth of research questions which must be assessed in chemical 
risk assessment. Additionally, in striving for robustness, systematic review makes significant 
demands on time and resources. Such demands are at odds with the increasingly strained 
availability of resources in chemicals policy (Pool & Rusch, 2014). These challenges are 
discussed further in Chapter 2, before the proposition of a methodological solution.  
 
Objective 2: Seek methodological solutions which facilitate the uptake of systematic 
review and other evidence-based approaches in chemical risk assessment. 
Chapter 2 identifies systematic evidence mapping as a promising methodological solution for 
overcoming many of the barriers associated with pursing evidence-based approaches to 
chemical risk assessment. A systematic evidence map (SEM) is a queryable database of 
references, data and meta-data which provides a use with computational access to the wider 
evidence-base. SEMs share much of their methodology with systematic review (see Table 2 of 
Chapter 2), but do not synthesise an overall conclusion and are not motivated by a single 
specific research question (Clapton et al., 2009; James et al., 2016). Instead, the purpose of a 
SEM is to characterise the evidence base more broadly – such that trends in the type, 
availability and outcomes of research can be investigated by end-users. This facilitates the 
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rapid identification of issues of emerging concern and allows resources to be more efficiently 
targeted (e.g. by focusing primary research efforts on evidence-gaps and secondary research 
efforts on evidence-clusters). Additionally, the breadth of SEMs allows a single mapping 
exercise to meet the needs of several, varied end-users – maximising the return on resource 
investment for these evidence-products.  
 
To some degree, the IUCLID database which houses chemical risk assessment data for REACH 
already emulates the output of a systematic evidence map – although the data it houses 
remain unsystematically curated, and inaccessible for broader query by varied stakeholders.  
Introducing systematic evidence mapping methodology offers a potential resolution of these 
issues.  
 
Objective 3: Characterise methodological solutions in the context of environmental 
health and toxicology, identifying specific adaptations required for chemical risk 
assessment. 
Systematic evidence mapping conceptualises the barriers associated with implementing 
evidence-based methods as a problem of data management and access, approaching the issue 
with the transparency and robustness associated with systematic review. Although novel to 
chemical risk assessment, the methodology has been successfully applied in the social and 
wider environmental sciences (Clapton et al., 2009; James et al., 2016). Chapter 3 studies this 
successful application for lessons applicable to adapting the methodology for environmental 
health.  
 
By conceptualising current evidence mapping practice through the lens of environmental 
health, Chapter 3 identifies key methodological considerations of relevance to chemical risk 
assessment applications. Most notably, this chapter demonstrates how the rigid, tabular data 
15 
 
structures favoured in current evidence mapping practice are ill-suited to housing 
environmental health data. This is owed to the complexity of environmental health data – 
which is not only highly heterogeneous, but also highly connected. Looking beyond 
traditionally employed databasing solutions, Chapter 3 identifies knowledge graphs as the 
future of evidence-mapping in environmental health. The flexibility of the graph data model, 
and its ability to preserve complex connections increases transparency and access to the 
evidence-base and is readily compatible with increasing research efforts in machine-learning 
and automation within the field.  
Objective 4: Explore the practical application of these methodological solutions to 
environmental health research problems, identifying remaining challenges and 
clarifying the direction of future work. 
Interest in systematic evidence mapping is beginning to accelerate in the field of 
environmental health (e.g. (Beverly, 2019; NTP-OHAT, 2019; The Endocrine Disruption 
Exchange, 2019a)), with the first protocol for an environmental health SEM recently published 
in the Environment International journal ((Pelch et al., 2019), Appendix). However, the 
demand for computational expertise in databasing and data modelling threaten accessibility 
of the methodology for the wider research community, and perpetuate the production of 
manually produced, low-resolution evidence maps. Thus, to sustain interest in developing the 
methodology to its full potential, Chapter 4 illustrates a proof-of-concept case study using the 
graph data model for mapping environmental health data.  
 
In this chapter, a scoping review on the use of National Health and Nutrition Examination 
Survey (NHANES) datasets is expanded using an evidence-mapping approach and graph-based 
data model. This chapter aims to illustrate the greater return of the graph data model for 
evidence mapping by comparing this methodology to that of the corresponding scoping 
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review. It serves to raise the profile of graph-based data modelling in environmental health, 
and seeks to clarify a direction for future work in this field.  
The flexibility of the graph data model, and its ability to maintain the complex relationships 
connecting datasets, could offer much to evidence mapping at scales akin to the REACH IUCLID 
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Conducting systematic reviews in environmental health and toxicology requires that the 
methodological quality of primary studies included in reviews is assessed in a consistent, 
robust and transparent manner. However, the considerable variation in design and conduct 
among primary studies from a diverse range of fields, all of which may be eligible for inclusion 
in a single environmental health systematic review (Rooney et al., 2016), makes this a 
significant challenge. Studies of different design are prone to different specific systematic 
errors (biases) (Rooney et al., 2016). While many of these biases are well described – the 
specific impacts that these biases have on the overall results of a study (i.e. the direction and 
relative magnitude of the systematic errors they introduce) are understudied in environmental 
health and toxicology – and further complicated by study designs in which isolating the effects 
of a single source of systematic error is difficult (e.g. epidemiological studies) and/or by the 
empirically inaccessible nature of the “true” result of an effect under investigation in a study. 
However, within the field of medicine, meta-epidemiological studies have assessed the 
relative impacts that certain biases have on the results of a study. Several of these biases may 
be directly applicable to toxicology studies (Rooney et al., 2014). For example, failure to 
randomly assign study participants to intervention or control arms of a clinical trial can be 
likened to failure to randomise animals to exposure or control groups of an in-vivo toxicology 
study. Similarly, environmental epidemiology studies note the opposing directions that certain 
biases can operate e.g. differential misclassification bias can skew results away from null, 
whereas the healthy worker effect can skew results towards null (McMichael, 1976; Rothman 
& Greenland, 1998). More explicit mention of these toxicological and epidemiologically 
relevant sources of bias are being incorporated into the revision of this manuscript – such that 
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relatable examples improve the accessibility of the manuscript for environmental health 
practitioners. 
 
As systematic review is still relatively novel in toxicology and environmental health, there are 
relatively few examples of tools developed for assessing the risk of bias of primary studies 
included in environmental health systematic reviews. Those that are available (such as the 
Navigation Guide (Woodruff et al., 2011; Woodruff & Sutton, 2014) and OHAT’s Risk of Bias 
Rating Tool for Human and Animal Studies (OHAT, 2015) discussed in the current version of 
the manuscript) will not cover bias domains and signalling questions applicable or suitable to 
all study designs within environmental health. Therefore, conducting systematic reviews on 
environmental health topics may necessitate the development of new appraisal tools which 
guide reviewers through the assessment of biases specific to certain fields or study designs 
e.g. the RoB-SPEO tool (Pega et al., 2020) – which was very recently developed for the 
assessment of biases specific to studies estimating the prevalence of exposure to occupational 
risk factors. 
 
Qualitative, domain-based approaches to assessing risk of bias provide a best practice 
framework with sufficient flexibility for adaptation to specific fields or novel study designs. 
Ensuring that qualitative, domain-based approaches are adopted in such scenarios – and that 
quantitative scoring approaches to risk of bias assessment are avoided, is a key aim of this 
manuscript. As well as highlighting existing tools that adopt the best-practice of qualitatively 
assessing risk of bias in a domain-based fashion, the revision of this manuscript further draws 
on examples of numerical appraisal tools which have traditionally been employed, or are 
currently being employed, in other areas of toxicology and chemical risk assessment e.g. the 
Klimisch Criteria (a numerical judgement system for assessing reliability, relevance, and 
adequancy of data to be included in a chemical hazard or risk assessment (Klimisch et al., 
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1997)), the Newcastle-Ottawa Scale (a numerical scoring system for assessing the quality of 
primary nonrandomised studies included in a systematic review, originally developed for 
medicine but popular in environmental epidemiology (Wells et al., 2014)) and the recently 
developed numerical assessment tool developed by the EPA for application of systematic 
review to TSCA risk assessments (EPA, 2018). This is to better evidence the persistent threat 
of scoring-based practice in the field.  
 
Finally, the illustrative scoring models in the current version of the manuscript (designed to 
illustrate the fundamental flaws of quantitative approaches to risk of bias assessment) are 
being further developed in the revision. Additional models which account for scenarios in 
which numerical scoring systems attempt to weight assessment criteria, and/or account for 
the direction of bias, are being incorporated into the revision and contrasted against the use 
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Systematic review is gaining popularity in environmental health as a robust and objective 
means of pursuing more evidence-based approaches to decision-making. A key part of the 
systematic review workflow is the critical appraisal step, in which the risk that evidence 
collated from primary studies is biased, is assessed by members of the review team. There is 
a wide range of tools available to help reviewers conduct this quality appraisal step, with 
quantitative scales (which produce an overall summary score) being particularly popular. 
However, published methodological guidance for conducting critical appraisal in 
environmental health systematic reviews advocate for a qualitative, structured and domain-
based approach, eschewing the use of quantitative scales. In this commentary, we explore 
why this is the case – presenting a theoretical, visual exploration of how quantitative scales 
and summary scores fail to appropriately represent magnitude of bias.  
Introduction 
Environmental health (EH) encompasses a diverse range of disciplines producing a significant 
volume of heterogeneous but highly interwoven data, spanning evidence from human 
epidemiology studies to in vitro experiments. Considering data from all such avenues provides 
a fuller understanding of the effects that environmental exposures can have on human health. 
This is vital for evaluating and informing risk-management and regulatory decision-making. 
However, the growing volume and scope of environmental health data presents a challenge 
for its translation into regulatory outcomes. This has led to a growing interest in the 
application of evidence-based approaches to environmental health (e.g. (EPA, 2018; The 
National Academies of Sciences, 2017; World Health Organization, 2019).  
23 
 
Evidence-based approaches advocate for the identification and use of all relevant, pre-existing 
evidence for evaluating environmental health risks and mitigation strategies. They seek to 
increase the precision of risk-management decisions and to reduce the bias associated with 
analysing cherry-picked and non-representative subsets of an evidence base.  
Among evidence-based approaches to evaluating environmental health risks, systematic 
review (SR) offers an objective, robust and transparent methodological framework for 
pursuing evidence-based approaches to decision-making, describing an extensive and 
comprehensive process for synthesising or integrating evidence in answer to a specific 
research question. Originally developed in the clinical and social sciences (Chalmers et al., 
2002; Lau et al., 2013), SR methodology is now being adapted for the context of environmental 
health (Hoffmann et al., 2017; Whaley et al., 2016). Several examples of detailed 
methodological guidance for conducting environmental health SRs have been published, 
including the Navigation Guide (Woodruff & Sutton, 2014), the National Toxicology Program’s 
Office of Health Assessment and Translation (NTP-OHAT) (NTP, 2015), the Texas Commission 
on Environmental Quality (Schaefer & Myers, 2017), and the SYRINA framework (Vandenberg 
et al., 2016), among others.  
The above SR frameworks detail the formulation of well-focused research questions and the 
process of devising, documenting and conducting the steps required to answer such questions 
using existing evidence. Each step can be broadly categorized as belonging to one of three 
phases of the systematic review process: identifying evidence of potential relevance to 
addressing the research question; appraising this evidence; and synthesising or integrating 




Figure 1: Key phases of the systematic review process. 
Fundamental to the SR workflow is the critical appraisal step, in which the strengths and 
limitations of included studies are characterised. This step is necessary for allowing the final 
results of a SR to be contextualised in terms of the overall quality of the evidence base. In 
conducting a SR, it is not only important to synthesise a pooled result through combining 
multiple studies, but also to determine how trustworthy that pooled result is (Morgan et al., 
2016).  
Although the importance of the critical appraisal step in systematic reviews is well established 
(Juni et al., 2001; Lundh & Gøtzsche, 2008; Moja et al., 2005), there appears to be less 
consensus on how this step should be conducted. This is evidenced by the variety of tools 
designed for this purpose (see reviews by Deeks et al., 2003; Krauth et al., 2013; Samuel et al., 
2016), which range from quantitative approaches that promote assessing primary study 
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quality with summary scores and numerical scales (e.g. Wells et al., 2014) to more qualitative 
approaches that promote assessing primary study quality on a narrative scale.  
The critical appraisal steps of the SR frameworks published by both the Navigation Guide and 
NTP-OHAT target internal validity, which is assessed  via a qualitative, domain-based analysis 
of risk of bias, and eschews quantitative scoring  (NTP, 2015; OHAT, 2015; Woodruff & Sutton, 
2014). This follows the recommended approach of Cochrane (Cochrane Community, 2019; 
Higgins & Green, 2011). In this commentary, we explain why this type of approach should be 
considered sound practice in EH SRs. We highlight the significance to SR of what these 
approaches assess (internal validity via risk of bias), how they assess it (using a qualitative scale 
evaluated on a domain-by-domain basis) and why they assess it in this way (why they do not 
advocate for a quantitative approach).  
Why critical appraisal of studies included in a SR should target 
internal validity 
The concept of “quality” when it comes to research is ambiguous, covering a variety of 
concepts of differing breadth and subjectivity. Characteristics of a study which are regularly 
identified in critical appraisal tools as contributing to being of “high quality” include: relevance 
to solving a research problem (Downs and Black 1998); how comprehensively the methods 
and results of a study have been reported and how easy the report is to understand (reporting 
and transparency) (Jadad et al. 1996); how likely the study is to suffer the impacts of random 
error (precision) (De Vet et al. 1997); how likely it is that the results of a study will be subject 
to systematic error or bias (Higgins et al., 2011); whether a study is sufficiently sensitive to 
detect the effect of interest (Cooper et al., 2016); and whether the study design conforms with 
a recognised international standard (Klimisch et al., 1997), among others.  
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However, in conducting a SR it is propensity for systematic error which should be the target of 
critical appraisal at the level of the individual study (Higgins et al., 2011). Systematic errors are 
reproducible inaccuracies, capable of introducing a consistent bias to the results of a primary 
study, resulting in either an over- or under-estimate of the true value of the effect under 
investigation. As systematic reviews are concerned with synthesising the results of primary 
studies, it is important that these systematic errors are not unwittingly carried forward to the 
synthesis step of the SR, where they would introduce bias to the overall conclusions of the 
review. Since the trustworthiness of this summary result is a direct function of the 
trustworthiness of the results of the individual included studies, it follows that it is the 
propensity of the design and conduct of each included study to introduce systematic error (i.e. 
bias) which must be targeted during critical appraisal. The extent to which the methods 
employed in a study are sufficient to prevent bias is equivalent to the extent to which a study 
is “internally valid”  (Hartling et al., 2009).  
Quality constructs other than internal validity will be relevant in critical appraisal contexts 
outside the systematic review of an environmental health risk. For example, reporting quality 
is a key construct for assessment during peer-review of scientific manuscripts to ensure 
transparent, comprehensive and concise reporting of methods and findings to the prospective 
reader. However, when conducting a systematic review with the objective of elucidating 
relationships between environmental exposures and subsequent health effects, the construct 
which matters is the one which directly affects that determination, i.e. potential for systematic 
error or bias.  
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Why critical appraisal should not use a quantitative scale and/or 
summary score to describe risk of bias  
Having argued that assessing bias should be the primary focus of a systematic review's critical 
appraisal step, we now demonstrate why scoring systems should not be used to conduct this 
task. We do this in three steps: firstly, we show how scores do not reliably correlate with 
magnitude of systematic error, such that a high score can be consistent with a low degree of 
bias and vice versa; secondly, we argue that although calibration of a scoring system would 
address this issue, it is very unlikely to be practically achievable; thirdly, we argue that scales 
and checklists discourage the deeper level of subjective engagement with the quality of 
included evidence which SRs need to properly contextualise their results.  
1. Scores do not reliably correlate with magnitude of systematic error 
In this section, we show how scores do not reliably correlate with magnitude of systematic 
error, such that a high score can be consistent with a low degree of bias and vice versa. To do 
this, we present two models of bias, which we refer to as the “Simple Model” and the “Revised 
Model”. The Simple Model exposes false assumptions made by linear scoring models in 
describing risk of bias. Correcting for these assumptions in the Revised Model then 
demonstrates how summary scores fail to scale with magnitude and direction of systematic 
error. 
The Simple Model: At their simplest, quality scales operate by awarding individual points to a 
study for conforming with each item on a list of n criteria, with 0 out of n being the worst, and 
n out of n being the best possible quality scores. Table 1 depicts a simple model scale based 
on nine criteria, A-I. The specific methodological standards underpinning A-I are arbitrary for 
the purposes of the model, but can be considered to represent study design features which 
would safeguard a study from the introduction of bias. These features might involve e.g. 
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ensuring that comparator or control groups are otherwise treated identically to exposure 
groups, ensuring that outcome assessors are blinded to the exposure status of participants in 
epidemiology studies (or animals in toxicology studies), that all potential confounders in 
epidemiology studies have been identified and appropriately accounted for, etc. (OHAT, 2015; 
Rooney et al., 2014). One point is awarded for every such criterion a study fulfils, giving a 
discrete scoring range of 0 to 9 out of a possible 9. Table 1 illustrates how a study might score 
4 out of 9 by complying with criteria C, F, G and H. There are multiple further possible ways of 
obtaining a score of 4/9, so long as a study complies with any four of the nine criteria.  










Total Score 4 
 
Table 1: A simple quality scale comprised of nine quality criteria, (A to I), which each 
represent a different aspect of quality within a study (e.g. use of controls, blinding, etc.). One 
point is awarded for every criterion fulfilled, and points are subsequently summed to 
produce an overall score (e.g. 4 out of 9). 
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Since a score of 4/9 has the same meaning regardless of the specific criteria met in order to 
achieve the score, it follows that each criterion from A to I contributed equal weight to the 
overall quality score. In evaluating the bias of primary studies during a systematic review, 
simple scales such as this are therefore assuming that the magnitude of bias introduced to the 
study count equal for every criterion that is not met. In other words, the simple model assumes 
that each unmet criterion introduces the same degree of systematic error. This is represented 
in Table 2, where failure to comply with any criterion is assumed to introduce 10 units of 
systematic error. Table 2 shows how three different studies with three different sets of 
limitations, and therefore different sets of unmet criteria, are scored. In the Simple Model the 
sum total systematic error is equal for studies with the same score regardless of which unmet 
criteria introduced the error (Studies A and B, Table 2). As score increases the number of 
unmet criteria decreases, resulting in a proportional decrease in total units of systematic error 
(Study C, Table 2). The linear relationship between score and magnitude of error assumed by 
the Simple Model is shown in Figure 2.
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  Study A Study B Study C 














Magnitude of bias 
introduced 
A 10 ✘ 10 ✓ 0 ✘ 10 
B 10 ✘ 10 ✓ 0 ✓ 0 
C 10 ✓ 0 ✘ 10 ✓ 0 
D 10 ✘ 10 ✓ 0 ✓ 0 
E 10 ✘ 10 ✓ 0 ✓ 0 
F 10 ✓ 0 ✘ 10 ✓ 0 
G 10 ✓ 0 ✘ 10 ✘ 10 
H 10 ✓ 0 ✘ 10 ✘ 10 
I 10 ✘ 10 ✘ 10 ✓ 0 
Total  - 4 50 4 50 6 30 
 
Table 2:  The assumption that the magnitude of bias introduced by failing to meet a criterion is equal for all criteria allows a summary score to mean the 
same thing in all scenarios (e.g. Study A compared to Study B above), and allows the score to accurately scale studies; those with a higher score suffer a 




Figure 2: The Simple Model of scoring study quality assumes a linear, proportional 
relationship between magnitude of error and study score. As study score increases, bias 
decreases. 
The Revised Model: A key problem with the simple model is its underlying assumption that all 
criteria count equal in terms of magnitude of systematic error is false. There is good empirical 
evidence that different limitations in study design and conduct introduce different degrees of 
systematic error in comparable studies, and also that the same limitations will introduce 
different degrees of systematic error in different research contexts (Cochrane Methods Group, 
2017). For example, evidence from preclinical trials of treatments for glioma (brain tumour) 
show that failure to randomise animals to intervention and control arms introduces a larger 
bias than failure to blind study personnel (Macleod et al., 2015). The assumption that an equal 
magnitude of bias is introduced by different study limitations cannot therefore be sustained, 
and the Simple Model must be relinquished. 
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A more realistic picture of how scores actually represent bias can be developed by revising the 
assumption that all criteria count equal in terms of introducing systematic error. To do this, 
each unmet criterion is now assumed to introduce a different magnitude of systematic error 
(Table 3). We also relinquish the assumption that biases act in a single direction. For example, 
in epidemiology it is recognised that while recall bias resulting in differential misclassification 
can bias the apparent effect of an environmental exposure away from null, the healthy worker 
effect can bias the apparent effect towards null (e.g. McMichael, 1976; Rothman & Greenland, 
1998). This variation in direction of bias is represented in Table 3 by some criteria introducing 
positive systematic error, while others introduce negative systematic error.  
Under this more realistic model of bias, it becomes evident that different ways of achieving 
the same score will introduce different degrees of systematic error. This is illustrated in Table 
3, using the same examples of scoring 4/9 as presented in Table 2. Not only does a score of 
4/9 no longer mean the same thing in every context, but the variable and bidirectional nature 
of bias means that a higher score does not necessarily account for a lower overall sum 
magnitude of systematic error. This can be seen in the magnitude of bias for a higher score of 
6/9 (Study C in Table 3) being greater than a lower score 4/9 (Study A in Table 3). It follows 
that if quality criteria do not have equal value, then a higher quality score does not correlate 
with a lower risk of bias – in the Revised Model, a “better” study can be giving a worse result.
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 Study A Study B Study C 
Criterion Magnitude and 
















Magnitude of bias 
introduced 
A +10 ✘ +10 ✓ 0 ✘ +10 
B -5 ✘ -5 ✓ 0 ✓ 0 
C +30 ✓ 0 ✘ +30 ✓ 0 
D +40 ✘ +40 ✓ 0 ✓ 0 
E -25 ✘ -25 ✓ 0 ✓ 0 
F -10 ✓ 0 ✘ -10 ✓ 0 
G +15 ✓ 0 ✘ +15 ✘ +15 
H +10 ✓ 0 ✘ +10 ✘ +10 
I -5 ✘ -5 ✘ -5 ✓ 0 
Total  - 4 +15 4 +40 6 +35 
Table 3:  Removing the assumption that the magnitude of bias introduced by failing to meet a criterion is equal for all criteria breaks the ability of the same 
score to represent the same magnitude of bias (e.g. Study A compared to Study B above). Additionally, removing the assumption that bias is unidirectional 
breaks the ability of a score to scale with quality, as it is no longer true that a higher score necessarily accounts for a lower sum magnitude of bias compared 
to a lower score (e.g. Study C compared to Study A).
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The full range of values for the Revised Model, based on bias values presented in Table 3, is 
shown in Figure 3. This is calculated on the basis of there being one way of scoring 9/9 or 0/9, 
nine ways of scoring 8/9 or 1/9, thirty-six ways of scoring 7/9 or 2/9, and so forth. Since scoring 
follows a probability distribution, there are 512 possible scoring combinations in total. Figure 
2 shows how each score (apart from 0/9 or 9/9) is consistent with multiple different sum total 
introductions of systematic error: a score seemingly indicative of high study quality (e.g. 7/9 
or 8/9) can equate to an equal or larger degree of systematic error than scores indicative of 
lower quality (such as 3/9 or 4/9). The scores are collapsing a wide range of potential for 
systematic error into a single summary figure, therefore obscuring rather than revealing the 
effect of methodological shortcomings on the extent to which a study’s results are likely to be 
biased.  
 
Figure 3: Revising the assumptions underpinning the Simple Model. Expanding on Table 3, 
the total magnitude of bias associated with every possible way of achieving a score on the 
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artificially generated scale is displayed, illustrating the range of meaning a single score might 
serve to mask.  
 
2. Scales cannot readily be calibrated  
In our illustrative evaluation of how summary scores cannot realistically represent bias, we 
have assumed that all the studies used as examples in Tables 2 and 3 are of the same type, 
designed to assess results for a shared research context, and therefore similar in overall study 
design. This is not representative of real-world environmental health systematic reviews, 
which will synthesise or integrate studies of varied design to obtain a summary result. 
Empirical evidence shows that differences in context have a large impact on how limitations 
in study design can bias the effect estimate of a primary study (Balk et al., 2002; Berkman et 
al., 2014), such that magnitude of bias introduced by a particular limitation in design or 
conduct will vary depending on the type and design of the study in which it is found (Cochrane 
Methods Group, 2017). For example, evidence from patient blinding techniques in clinical 
trials has shown that when patients are not blinded to treatment, intervention efficacy is 
exaggerated but the degree of bias varies according to study design (Hróbjartsson et al., 2014); 
and in studies in which investigators are not blinded, whether the outcome is objective (such 
as mortality) or subjective (such as patient reported pain levels) affects the magnitude of bias 
which failure to blind introduces (Wood et al., 2008). 
While scales could in theory weight their scores according to whether e.g. blinding was 
occurring in the context of a subjective or objective outcome, in practice researchers would 
end up in a situation where, in order to accurately represent systematic error, each scale 
would have to be adapted for each individual study design. Even if this did not arguably defeat 
the purpose of a scale, which is to be readily applied by the user as a measure of quality in 
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multiple situations, such calibration would require knowledge of exactly how much bias a 
limitation in design and conduct of a study will introduce to its results.  
Acquiring information for calibration either requires a near-perfect version of a study to have 
been conducted against which the study under appraisal can be compared, or it requires meta-
epidemiological research designed to determine the relative effect a methodological 
limitation has on the findings of a group of otherwise sufficiently comparable studies. Near-
perfect studies, such as sufficiently-similar randomised trials against which an observational 
study can be compared are almost always either unethical, or simply impractical. Even where 
this gold standard is available, where an exceptional observational study might provide a 
reasonable benchmark for comparison, there is little guarantee that any given observed effect 
represents the true effect because the true effect is empirically inaccessible (Groenwold and 
Rovers, 2010); (Jadad and Enkin, 2008). When it comes to meta-epidemiology, there are rarely 
enough studies to power precise analysis of the effect of e.g. failure to blind in various research 
contexts (Giraudeau et al., 2016) - let alone produce enough data to permit a scoring scale to 
be calibrated for each study design likely to be included in a systematic review . 
Scale calibration is therefore beyond the practical reach of most research teams working in 
most systematic review contexts (Balk et al., 2002; Berkman et al., 2014). This makes the 
process of appraising studies for bias in the majority of circumstances a qualitative, subjective 
process. 
3. Scores mask the subjectivity of appraising studies for risk of bias 
Despite theoretical (Greenland & O’Rourke, 2001) and empirical (Jüni et al., 1999) arguments 
against numerical approaches to critical appraisal, and over a decade of official guidance 
arguing against their use (Higgins & Green, 2009), scales and scoring systems continue to be 
popular (Beronius & Hanberg, 2017; EPA, 2018; Wells et al., 2014; Schneider et al., 2009). In 
addition to ease of use, the persistence of scales may in part be due to a perceived need to 
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resist subjectivity when conducting assessments which are supposed to be objective and 
scientifically robust; such are the values of systematic review. Using scales and checklists may 
offer an impression of objectivity by producing a fixed numerical summary which appears to 
involve minimal subjective interpretation.  
However, in attempting to limit the subjectivity of interpretation, simply scoring a list of 
quality constructs does not do enough to elicit further discussion or justification from the 
reviewer. This compromises the transparency that is fundamental to the systematic review 
process. Furthermore, because presenting a summary score in lieu of the explicit reasoning 
behind reviewers’ judgements masks the subjective judgements involved in reaching the 
score, it arguably encourages the sort of inconsistent and subjective interpretation by users of 
the review that quality scales are seeking to avoid (Shamliyan et al., 2010).    
Masking subjectivity in this manner also has the potential to stymie the progression of risk of 
bias assessment and related tools, especially in the fields of environmental health, toxicology 
and chemical risk, where systematic review is gaining prominence. It does not encourage 
understanding and appreciation of factors important for reducing bias in different 
experimental designs. The attempted rigidity of the scales leaves little room for 
accommodating innovative study designs, as studies are only expected to rate favourably in a 
risk of bias assessment if they fulfil the criteria the makers of the scale dictate as valid 
(Groenwold and Rovers, 2010).  
Where scales attempt to simplify and render objective the process of evaluating risk of bias, 
they instead create a system whereby not only are the scales used to assign points to a study 
based on a subjective process, but the overall summary score presented to the reader remains 
open to interpretation (Sanderson et al., 2007). This makes scales a poor choice for thorough, 
robust and transparent systematic reviews. 
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Domain-based assessment of risk of bias as a response to the 
shortcomings of scores and scales  
Since magnitude of bias cannot normally be measured, and scores cannot reliably represent 
magnitude of bias, studies included in a SR have to be appraised for bias on a case-by-case 
basis. This is best conducted by targeting risk of bias, and managing subjectivity through a 
domain-based risk of bias assessment.   
1. Targeting risk of bias 
While the precise extent to which any given study is biased cannot be readily quantified, there 
is good empirical evidence from meta-epidemiological research  (e.g. Bolvig et al., 2018; 
Crossley et al., 2008; Dechartres et al., 2016) that certain methodological features consistently 
introduce systematic error to the results of a study. These include failure to blind study 
personnel to experimental and control arms of a study, not controlling for important 
confounders in observational studies, etc.  
It can be assumed that, if a study has methodological features which have been shown 
elsewhere to introduce bias, then the study is at least at risk of likewise being biased - even if 
that risk may only be characterised qualitatively (Higgins & Green, 2011). Since most meta-
epidemiological evidence for risk of bias comes from healthcare research, it is arguably even 
more important to characterise risk qualitatively, pending more detailed information about 
how study design variables can introduce systematic error into environmental health study 
results. While the precise magnitude of bias cannot be known, it should still be possible to 
come to a meaningful judgement as to whether the probability and likely direction and 
magnitude of bias in the study is important enough that it should reduce confidence that the 
reported results of the study in question are true. 
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2. Manage subjectivity through domain-based assessment of risk of bias 
The process of managing subjectivity can be promoted through the use of  domain based 
approaches to assessing risk of bias, such as those utilised by the Navigation Guide (Woodruff 
& Sutton, 2011, 2014) and by OHAT’s Risk of Bias Rating Tool for Human and Animal Studies 
(OHAT, 2015), both of which are adapted from the Cochrane Collaboration’s Risk of Bias tool 
for non-randomised studies (Higgins & Green, 2009). As opposed to scales, which result in 
opaque, quantitative conclusions, domain-based systems consider each specified bias 
construct individually (O’Connor et al., 2015), eliciting consistent appraisal of key issues via a 
structured questionnaire format to reach a transparent, qualitative conclusion about risk of 
bias. Formatted as a framework for the kinds of bias that are likely to impact the effect 
estimate, reviewers are guided to consider appropriate factors and the relative significance of 
these factors within the context of individual studies. This promotes  distinction between the 
concepts of “quality” and “risk of bias” so as to account for scenarios in which studies may 
have been conducted according to the highest quality standards, but may still suffer a 
significant risk of bias – such as scenarios in which blinding may have been impossible (Armijo-
Olivo et al., 2012) – or may be poorly reported yet still at low risk of bias.  
Unlike scoring systems, domain-based risk of bias tools acknowledge the need for reviewers’ 
experiences and knowledge when considering which types of bias are likely to be significant 
given the context of the review. They account for subjectivity by managing it in a transparent 
manner, prompting reviewers to pre-specify how risk of bias will be handled in their protocol 
and requesting that reviewers provide justification and evidence for their judgements, 
allowing readers to decide whether they agree with the results (Higgins & Green, 2011; 
Rooney et al., 2014; Woodruff & Sutton, 2011) – an approach which provides the necessary 
balance between qualitative, subjective judgements and transparency about the context in 
which those judgements are being made. By not defining a priori the relative weight or 
importance of any one specific source of bias (within a domain) compared to another, 
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approaches following the same principles as the NTP-OHAT and Navigation Guide allow for the 
context-dependent nature of bias. Arriving at qualitative judgements promotes consideration 
of a study’s limitations and its context as a whole, rather than first considering limitations and 
only then assessing whether a study has these limitations, as is promoted in numerical scales.  
The major advantage of these qualitative, domain-based approaches is their potential to yield 
consistent appraisal of potential for systematic error, even when the “true” result of a given 
study is empirically inaccessible: they elicit from experts what they do know about study 
limitations, to a judgement consistent with what can realistically be inferred from those 
limitations given limited access to “true” results. To limit the extent to which expert judgement 
can reduce transparency and be itself a risk of bias in a systematic review, this subjectivity is 
managed by domain-based tools through their structured approach to critical appraisal.  
Conclusion 
Systematic review is still relatively novel in the field of environmental health. However, a 
growing appreciation of the importance of making evidence-based decisions which consider 
all available data continues to see increasing interest in the application of systematic review 
to environmental health contexts (Whaley et al., 2016). It is therefore vital to adopt 
methodology that eschews the use of scales and scoring systems for rating risk of bias at this 
early stage, to avoid repeating the mistakes and learning the same hard lessons experienced 
in the medical field.  
Where scales have tried to simplify and objectify the evaluation of risk of bias, they have 
instead simply masked the subjectivity associated with its assessment. Combining this with 
their inability to represent the true nature of bias makes scales a poor choice for thorough, 
robust and transparent systematic review. Qualitative domain-based approaches, on the 
other hand, offer a process for acknowledging and managing subjectivity.  
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Acknowledging the role of subjectivity, rather than hiding it behind a summary score, is 
currently the most transparent means of tackling the inherent subjectivity associated with 
assessing primary study quality. In an area as complex as risk of bias assessment, there may 
even be significant value in some degree of subjectivity. So far as this is transparently justified, 
the freedom to be subjective may result in a well-considered appraisal of included studies, 
particularly where unique or emerging study types are concerned, leaving room for 
progressive debate, review and future improvement. This is likely to be particularly important 
in chemical risk assessment, a field ever pressured to adopt new and alternative toxicity 
testing procedures, the quality of which cannot be appropriately accounted for by rigid scales. 
However too much freedom in assessing risk of bias may have the opposite effect, providing 
insufficient means of focusing the process or holding reviewers accountable for their 
judgements, creating confusion and inconsistency, and resulting in a backward slide to the 
well-documented challenges with narrative appraisals of quality of evidence (Chalmers et al., 
2002). It would therefore seem that the most suitable means of assessing risk of bias must 
target a middle ground, neither masking subjectivity nor giving it free reign, but rather 
“managing” it. 
Well-managed and open consideration of the limitations, not only of the primary studies, but 
of the methods used to assess them, has the potential to increase the reliability of chemical 
risk assessment conclusions. Assessing risk of bias in a domain-based manner should allow a 
wider variety of resources to inform risk assessment, increasing the precision of safety 
estimates, and reducing the research waste and costs associated with repeat testing.  
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Working around rigid schema and lowering resolution 
Attempting to balance the rigidity of a schema with the fluidity or heterogeneity of the data it 
organizes might lead environmental health (EH) mappers to compromise the resolution of 
their data extraction and coding. Consider a set of heterogeneous in-vitro studies which meet 
the inclusion criteria of a systematic evidence map (SEM) exercise. Avoiding extracting specific 
study detail in favour of more broadly applicable study features (e.g. type of cell tested) allows 
those studies to occupy the same schema and avoids the need to update the schema, as all 
future encountered studies will likely contain the broad extracted study feature. Coding 
heterogeneous studies with a broad controlled vocabulary term can have a similar effect if this 
code is provided in lieu of raw data– e.g. broadly coding both a study investigating the 
contaminants in drinking water, and another investigating air quality as “environmental 
monitoring”. 
A preference for producing lower resolution maps was noted in the survey of CEE’s current 
mapping practice, where only broad or even censored data were included in systematic map 
databases (e.g. Gumbo et al., 2018). The majority of maps also appeared to provide only the 
broader controlled vocabulary code in lieu of the raw extracted data to which the code was 
applied. 
Beyond allowing heterogeneous or complex data to fit within a rigid structure, several 
additional motivators might contribute to the current preference for producing low resolution 
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systematic maps. Lower resolution maps represent a less severe demand for time and 
resources - making their outputs more achievable given the currently manual nature of 
systematic mapping. Mappers may also wish to prevent end-users from drawing inappropriate 
or premature conclusions based on data which has not been critically appraised by censoring 
specific results or data relationships. Alternatively, a lower resolution map may already be fit-
for-purpose, and thus the most efficient and easily understood form of mapping exercise. 
However, there are several drawbacks associated with the practices that result in low 
resolution maps. Transparency is reduced when end-users cannot access the raw data to 
which a code has been applied, and therefore cannot assess whether they agree with the 
application of that code. Data integrity is compromised when the relationships between broad 
coding categories are unrepresentative of the raw data, or when incorrect relationships are 
inferred between broad data fields. Accessibility of the data for end users wishing to query the 
systematic map is also limited to a narrower range of broad questions, restricting application 
of the map to the use-cases defined by the developer rather than meeting the potentially 
unanticipated needs of the user. Thus, while a SEM which facilitates identification of low-
resolution trends might be an efficient research tool in other fields, the demands of chemicals 
policy for detail and contextual value limit the utility of these exercises for this application. 
Finally, although low resolution maps might represent a smaller upfront cost in terms of time 
and resources – they may represent a less efficient approach in the long-term. Details omitted 
from a map which later become important or relevant for updated chemical risk assessment 
procedures means that data extraction efforts must be repeated. Similarly, although 
extracting and storing high-resolution semantic triples in a knowledge graph may incur higher 
demands on time/resources in the short term, the preservation of referential integrity in the 
graph means that the mapping exercise need not be repeated in order to facilitate a user’s 
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The National Health and Nutrition Examination Survey (NHANES) is a large, cross-sectional 
human biomonitoring program in the United States (US). Among the variables measured in 
the survey are biomarkers of exposure to hundreds of manufactured chemicals which are of 
interest to chemical risk assessment and chemicals policy applications. The NHANES datasets 
are publicly available and offer a unique opportunity for crowd-sourcing analysis efforts. This 
allows researchers with varied interests to uncover a broad range of toxicologically relevant 
associations between survey variables and ensures maximum return of the resources input 
into the survey. However, these analyses are typically published in the academic literature in 
unstructured formats. This makes it difficult to gain a broad overview of which associations 
have been studied, and whether there are any potential links between such associations which 
might inform future analyses. This is an issue which has traditionally been addressed through 
scoping review. Limitations in the outputs of scoping reviews make them difficult to update 
and compromise their broader utility for characterizing and exploring existing research. In this 
manuscript, we explore the future of such evidence-surveillance exercises by conducting a 
small-scale, graph-based systematic evidence mapping exercise, in which literature reporting 
exposure-outcome associations for the NHANES datasets are mapped. We highlight the 
efficacy of the graph data model for preserving data integrity of increasingly complex and 
highly resolved datasets – contrasting our approach to an equivalent scoping exercise. Finally, 







The National Health and Nutrition Examination Survey (NHANES) is a large, continuous, cross-
sectional biomonitoring program in the United States. Every year, a representative sample of 
the US population are recruited to participate in questionnaires, interviews, physical 
examinations and/or biological sampling (Centers for Disease Control and Prevention, 2019a; 
Sobus et al., 2015). In addition to biomarkers of nutrition, health and communicable disease - 
NHANES measures biomarkers for hundreds of manufactured chemical exposures in samples 
of urine, whole blood, plasma or serum (Centers for Disease Control and Prevention, 2019b). 
These measures, along with questionnaire, interview and examination data, are made publicly 
available through the Centers for Disease Control and Prevention (CDC)’s website 
(https://www.cdc.gov/nchs/nhanes/index.htm).  
 
This accessible resource of human exposure data is of significant value to regulatory decision-
making in chemicals policy contexts, and has been described as a “a gold-mine of data for 
environmental health analyses” by the United States Environmental Protection Agency (US 
EPA) (EPA, 2003), with whom the CDC has a collaborative relationship. Analyses of the NHANES 
datasets are relevant to an array of health (Ahluwalia et al., 2016) and chemicals policy tasks, 
including: setting national reference levels for health-related variables and/or chemical 
exposures (e.g. CDC, 2001); monitoring trends in health-variables (e.g. disease prevalence) 
and/or chemical exposure (EPA, 2003); assessing the efficacy of policy interventions to control 
chemical exposure (e.g. through phase outs of toxic substances (Easthope & Valeriano, 2007)) 
or health-outcomes (e.g. through vaccination programmes (Markowitz et al., 2013); 
identifying disparities in the exposure/health variables associated with specific sub-
populations (e.g. Kobrosly et al., 2012; Nelson et al., 2012; Tyrrell et al., 2013); and assessing 




The open access model of NHANES presents a unique opportunity for “crowd-sourcing” 
analyses. This means that researchers from across the globe are able to access and analyse 
NHANES data, finding trends and associations of potential interest to federal agencies and the 
wider research community. Thus, the potential returns of the survey are maximised - 
improving resource efficiency. Further, the open accessibility of NHANES promotes 
collaboration and progression within environmental health, where pooled expertise builds a 
more complete understanding of the data and the statistical methods required for its analysis. 
At minimum, the open accessibility of NHANES promotes transparency - whereby analyses can 
be verified through independent replication efforts (e.g. Brown et al., 2019).  
 
However, analyses of NHANES datasets are not always as accessible as the raw data 
themselves - compromising the potential reach, impact and benefits of these crowd-sourced 
efforts. Difficulty accessing analyses may result in inadvertent but redundant duplication, 
which threatens the efficient allocation of resources to investigating associations of novel or 
emerging concern. For chemicals policy, a lack of accessibility further compromises 
consideration of such analyses in the risk assessment process - where associations are 
integrated with data from a range of heterogeneous evidence streams. 
 
A central, searchable resource which catalogues research conducted using NHANES data 
would therefore maximise its value for stakeholders. Such a resource would facilitate the 
meta-research required for identifying trends across analyses, characterising research gaps on 
which to focus crowd-sourcing efforts. Several reviews have addressed this need for 
monitoring and understanding the research space around the analysis of NHANES data (e.g. 
(Bell & Edwards, 2015; Taboureau & Audouze, 2017). One such review of particular relevance 
to chemicals policy is that of Sobus et al. (2015) - which focused on analyses concerning 
chemical exposures. Broad, “scoping” reviews such as Sobus et al. (2015) characterise the 
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research landscape through a process of searching for, screening, extracting and categorizing 
evidence. While providing a valuable overview of research activity, the static and inaccessible 
outputs of such reviews (e.g. in-text data tables and visualisations) continue to limit their 
broader utility. In other words, users are unable to query collated evidence according to their 
specific research interests and must instead re-extract and re-structure data as appropriate to 
their queries. These are the shortcomings which systematic evidence mapping aims to 
overcome (James et al., 2016; Wolffe et al., 2019).  
 
Systematic evidence mapping is an evidence-based methodology of growing interest in 
environmental health and toxicology (e.g. Beverly, 2019; Pelch et al., 2019), with wide 
potential application in regulatory workflows (Wolffe et al., 2019). It builds on the scoping 
review methods traditionally employed in evidence surveillance - with an emphasis on 
transparency, robustness and a broad, comprehensive coverage of the evidence landscape. 
The key output of a systematic evidence mapping exercise i.e. the systematic evidence map 
(SEM) itself, takes the form of a queryable database of references, extracted data and meta-
data. This computationally accessible output can be readily updated without duplication of 
data-extraction effort. 
 
In our previous work (Wolffe et al., 2020), we highlighted the utility of the flexible, schemaless 
graph data model for maintaining transparency and data integrity within SEMs. However, the 
application of graphs for evidence mapping in environmental health is still novel. To resolve a 
path toward graph-based approaches to evidence mapping in environmental health, we 
conduct an exploratory case-study in which we apply a graph-based approach for mapping 
exposure-outcome associations reported for the NHANES dataset - expanding on the outputs 




In addition to our findings regarding exposure-outcome associations - we highlight key 
advantages of the graph data model for evidence surveillance and systematic evidence 
mapping methodology and discuss the challenges and future work required to implement our 
approach at scale. Through this case-study, we aim to increase familiarity of the evidence 
synthesis community with the graph data model. We hope this bridging research will 
accelerate and unify efforts to make best use of existing data by better understanding the 





The primary aim of this mapping exercise is to conduct a methodological exploration of the 
graph-data model for systematic evidence mapping in a context relevant to chemicals 
regulation, and to compare this approach with traditional methods of evidence surveillance 
(e.g. scoping reviews). In using NHANES as a case study - the secondary aim of this mapping 
exercise is to explore which of the exposures and outcomes measured as part of NHANES have 
been investigated for association by the wider research community, and to identify the future 
research required to study these associations at scale.  
 
3.2 Dataset 
The complete set of 273 publications included by Sobus et al. (2015) in their scoping review 
on the use of NHANES data for chemical risk assessment were considered for inclusion in this 
mapping exercise. The search strategy and inclusion/exclusion criteria which generated this 
dataset can be found in the Methods and Supplemental Information of Sobus et al (2015). 
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Briefly, search strings covering the concepts of “NHANES”, the “United States”, and 
“biomonitoring” were combined with the “AND” boolean operator and filtered by publication 
dates which fell within the range 1999-2013. Results were screened by a single author (Sobus 
et al., 2015) at the level of title and abstract, and studies which exclusively reported use of 
“endogenous biomarkers (e.g. hormones, antibodies, inflammatory markers), tobacco-specific 
biomarkers (e.g. cotinine), dietary biomarkers (e.g. vitamins/nutrients, essential minerals), or 
biomarkers of phytoestrogens, isoflavonoids, or aflatoxin” excluded.    
 
3.3 Inclusion Criteria  
The full text of each of the 273 publications in the Sobus et al. (2015) dataset were screened 
for inclusion in this evidence mapping exercise by a single reviewer (TW). Only those which 
presented a statistical measure of association between a health outcome (i.e. a biological 
response or markers of biological response) and a chemical exposure were included.  
 
In their scoping review, Sobus et al. (2015) categorised each of the included publications 
according to whether they reported a “health association” or “exposure assessment”. Any 
discrepancies regarding the inclusion status of publications in this mapping exercise compared 
to the category which these publications were assigned by Sobus et al. (2015) were 
documented and justified (see Table S1) i.e. indicating if a publication which was categorised 
as “exposure assessment” has been included, or conversely if a publication which was 
categorised as “health outcome” has been excluded in this mapping exercise.  
 
3.4 Low Resolution Data Extraction  
A simple data extraction workflow was developed to assist with the collation of exposure-
outcome associations from included publications. Briefly, data extracted from included study 
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reports were divided into one of two categories: bibliographic information pertaining to the 
study report; or information pertaining to the studied associations. A relational database 
infrastructure was used to construct data extraction forms - whereby study reports were 
related to associations through a one-to-many relationship. This allowed the recording of 
multiple associations without manually repeating the bibliographic information in long-form, 
minimising extraction errors.  
 
Data recorded in the “bibliographic information” component of the data extraction workflow 
were as follows: 
• Reference ID (as assigned by Sobus et al., to facilitate comparison and validation) 
• Title 
• Authors 
• Publication Year 
  
Associations were defined as occurring between a chemical exposure and a health outcome - 
for which the results of a statistical measure of association were reported. Entities for which 
an association with chemical exposure was measured - but which represent exposures 
(including to other chemicals), non-health outcomes, covariates, adjustment factors or 
stratification variables (e.g. sex, age, smoking status etc.) were excluded. Likewise, 
associations in which neither entity was considered a chemical exposure (e.g. history of 
anaemia and head circumference) were excluded from extraction. Thus, data recorded in the 
“associations” component of the data extraction workflow were as follows: 
• Chemical exposure  
• Individual components of the chemical exposure, if applicable (e.g. ΣPFAS might 
comprise individual components of PFOA, PFOS and PFBS).  
• Biological medium in which the exposure was measured 
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• Associated health outcome 
 
Data were extracted by a single reviewer (TW) from the full-text pdf of each publication. As 
far as possible, data were extracted in a consistent manner by using consistent spellings and 
structures e.g. exposures reported as “PFOA”, or “perfluorooctanoic acid” were both 
extracted in the format “Perfluorooctanoic acid (PFOA)”.  
 
3.5 Data Processing and Graph-based storage 
A large, long-form data table (Table S2) was produced by querying the relational data 
extraction infrastructure. Chemical constituents were delimited as separate “repeating 
columns” (see Wolffe et al. 2020), and biological media concatenated with chemical exposure 
- so as to distinguish between e.g. Blood Cadmium and Urine Cadmium etc. Any exposures for 
which a biological medium was unreported were also extracted and represented as an 
independent exposure i.e. “Cadmium”, “Cadmium, blood” and “Cadmium, urine” were 
considered as different specific exposures. Any inconsistencies identified within each column 
(e.g. typos etc.) were manually amended.   
 
A graph data model was devised for representing the relationships between entities in the 
long-form data table, and is presented in Figure 1. The data within the table was processed for 
storage using an iPython Jupyter Notebook (Project Jupyter, 2019) (see Supplementary File 
S1) according to the graph data model in Figure 1. The py2neo package (Small, 2019) was used 
to connect with a Neo4j graph database instance (Neo4j, 2019) and the graph populated with 




Figure 1: Graph data model describing the relationships between publications and the 
exposure-outcome associations they report. Neo4j’s labelled property graph model was 
exploited to represent “RefID”, “Title”, “Authors” and “Year” as properties of Publication 
nodes.  
 
3.6 Applying Controlled Vocabulary Code  
10 of the 11 controlled vocabulary terms used to categorise studies by Sobus et al. were 
adopted in this mapping exercise i.e.“BFRs” (brominated flame retardants), “Dioxins, furans, 
PCBs” (polychlorinated biphenyls), “environmental phenols”, “metals/metalloids”, “other”, 
“PAHs” (polycyclic aromatic hydrocarbons), “pesticides”, “PFCs” (perfluorinated compounds), 
“phthalates” and “VOCs” (volatile organic compounds) . As individual chemical exposures were 
extracted in this exercise, the “multi-group” controlled vocabulary term was omitted. Where 
possible - the use of controlled vocabulary by Sobus et al. was mapped directly (see 
Supplementary File S2, Table S3), except for the exposures which would solely have been 
categorised as “multi-group”.  These exposures were manually re-assigned a controlled 
vocabulary label (see Supplementary File S2, Table S4 and Table S5). Code was incorporated 
93 
 
into the graph as nodes and connected to single/mixed chemical exposure nodes through a 
“CODED_AS” relationship (see Fig 2A). Similarly, a controlled vocabulary of 18 terms was 
developed iteratively for the categorisation of health outcome nodes. These terms were 
manually assigned to extracted health outcomes and represented in the graph with a 
“CODED_AS” relationship (see Fig. 2B). Where appropriate, more than one controlled 
vocabulary term was assigned to a single health outcome (e.g. “Mortality, cancer” was labelled 
with both the terms “Mortality” and “Cancer”). 
 
Figure 2: (A) Chemical exposure nodes are categorised by a “CODED_AS” relationship to 
nodes housing controlled vocabulary terms.  (B) Similarly, health outcome nodes are 
categorised by a “CODED_AS” relationship to nodes housing controlled vocabulary terms. 
Due to the variation and complexity of health outcomes, multiple controlled vocabulary 




3.7 Exploring Associations 
The evidence map was explored through a series of queries written in cypher (neo4j’s graph 
query language) using the py2neo package (see Supplementary File S3). The results of these 
queries were typically processed as pandas dataframes and visualised using a variety of tools, 




4.1 Included Publications and Number of Associations 
In total, we extracted 1656 investigated associations from 132 included publications. These 
associations encompassed 326 different chemicals and 265 specific health outcomes. The 
number of associations reported within a single publication ranged between 1 and 150, with 
a median value of 4.  
 
4.2 Exposures, Health Outcomes and Associations  
 
4.2.1 Exposures 
We found that the largest number of associations included in our map could be categorised as 
occurring between metals/metalloids and a health effect (see Fig. 3). A total of 86/132 
included publications reported at least one association between a health outcome and a 
chemical exposure within the metals/metalloids group (Supplementary File S3). Blood lead 
and urinary cadmium were the two most frequently associated specific chemical exposures 
within this group (Supplementary File S3 & S4). The metals/metalloids exposure category had 
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over twice as many studied associations as the next most populous chemical group; Dioxins, 
Furans, PCBs -  which were reported in only 9/132 included publications.  
 
 
Figure 3: The number of associations (x axis) which investigated a chemical exposure within 
each of the exposure categories (y axis), across all included publications.  
 
However, “Dioxins, Furans, PCBs” was also the most diverse exposure group, comprised of 110 
distinct chemical exposures (see Supplemental File 3). Thus, this exposure group was 
characterised by a low frequency of associations for many individual chemical constituents. 
The full make-up of each exposure category, and the frequency with which each distinct 
chemical within an exposure category is associated with a health outcome, is visualised in 
Supplementary File S4. “Dioxins, Furans, PCBs” was also the category most frequently assigned 
to associations which investigated mixed chemical exposures, followed closely by phthalates 
(Supplementary File S3). The number of individual chemical constituents comprising a mixed 
chemical exposure for any category ranged from 2 e.g. for “PCB-196 & PCB-203, serum (Cave 
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et al. 2010)” to 28 e.g. for “Non dioxin-like polychlorinated biphenyls (PCBs), serum (Gallagher 
et al. 2013a)” (Supplementary File S3). 
 
4.2.2 Health Outcomes  
The most frequently associated health outcome category was the “Body Weight and 
Metabolism” group (Fig 4.), which incorporated 61 specific health outcomes (Supplementary 
File S3 & S5) and was reported by 34/132 included publications (Supplemental File 3). A full 
break-down of the specific health outcomes associated with each outcome category, and the 
frequency of associations for each specific outcome can be found in Supplementary File S5.  
 
 
Figure 4:  The number of associations (x axis) which investigated a health outcome within 
each of the outcome categories (y axis), across all included publications.  
 
“Body weight and metabolism” was also the most diverse outcome category, with nearly 
twice as many specific health outcomes coded with the term as the next most diverse group; 





Figure 5A illustrates which exposure and outcome categories were most frequently associated 
with each other, and which were not studied for association at all. Associations between 
“metals/metalloids” and “body weight/metabolism” were the most prevalent, followed 
closely by “dioxins, furans, PCBs” and “body weight/metabolism”. “Metal/metalloids” was the 
only exposure group to have been associated (at least once) with each of the health outcome 
categories. Similarly, “body weight/metabolism” and “liver” were the only health categories 
to have been associated (at least once) with each of the exposure categories. Figure 5B 
illustrates how these associations are distributed across individual publications - indicating 
that associations between “metals/metalloids” and “heart and circulatory” outcomes were 
independently reported in the largest number of publications. The implications for analysing 





Figure 5: (A) Association-level heat map illustrating the frequency with which exposure and 
outcome categories have been associated, across all included publications i.e. a single 
publication reporting associations between “cadmium, blood” and “lipid levels” as well as 
“lead, blood” and “lipid levels” would count as two associations between 
“metals/metalloids” and “body weight/metabolism”. (B) Publication-level heat map 
illustrating the frequency with which independent publications report associations between 
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exposure and outcome categories i.e.  a single publication reporting associations between 
“cadmium, blood” and “lipid levels” as well as “lead, blood” and “lipid levels” would count 




This case-study mapping exercise expanded on the scoping review of Sobus et al (2015) by 
increasing resolution through extracting additional detail regarding exposure-outcome pairs 
for each included publication reporting a health outcome. In this exercise we did not present 
the direction, significance or statistical methods used to study associations - nor did we 
appraise the methodological integrity of the included studies. Thus, the presence of an 
association in this map is not indicative of a positive association or causative relationship 
between exposure and outcome - but simply of the fact that a study has investigated a 
relationship between those two variables.  
 
Inclusion of specific detail regarding results of included studies within systematic evidence 
maps is an issue for debate in the field - and has led to the practice of censoring evidence maps 
(e.g. (Gumbo et al., 2018). This censorship is borne out of a responsibility to ensure that data 
collated within an evidence map are not misinterpreted or misused, as validation and appraisal 
of included evidence is often beyond the scope of the evidence surveillance function served 
by SEMs. Such issues raise questions over the validity of exposure-outcome associations for 
NHANES datasets given limitations in the survey design and/or analytical methods employed 
in assessing associations (e.g. Christensen et al., 2014; Stone & Reynolds, 2003). However, the 
goal of evidence mapping is to make best use of all available data by improving computational 
access to an evidence landscape such that data can be critically analysed. It presents a neutral, 
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queryable account of what has been done or investigated within a field, regardless of whether 
and how that field “should” have conducted its investigations. Thus, although it may be 
appropriate in some cases (e.g. the production of user-interfaces for non-specialist audiences) 
censoring should not necessarily present a barrier to the resolution of evidence-maps.  
 
Disregarding censoring, limitations in the resolution of evidence maps are imposed by several 
other factors e.g. the prevalent use of rigid data structures which struggle to uphold referential 
integrity as the complexity of data increases with resolution (Wolffe et al., 2020). We discuss 
our simple and accessible exploration of the graph data model for handling this increase in 
complexity - focusing on the application and potential of graph-based methods for facilitating 
the production of highly resolved evidence maps. We compare our findings to scoping 
methods where appropriate, highlighting the remaining challenges which threaten resolution 
of evidence maps and the future work required to address these challenges through the lens 
of further expanding this NHANES mapping exercise. 
 
5.1 Mapping vs scoping exposure-outcome associations for the NHANES 
datasets  
In finding that “metals/metalloids” was the most prevalent exposure group, our results echo 
that of Sobus et al (2015), even without taking into consideration the publications which did 
not study a health outcome. This raises the question of fitness for purpose of evidence 
surveillance exercises, as the scoping methods employed by Sobus et al. are sufficient to 
broadly determine the most dominant features of the evidence landscape and are suited to 




However, this publication level assessment of the evidence base did illicit some results which 
were ambiguous, e.g. publications which fall into the “multi-group” category. Additionally, our 
results show the potential for considerable differences in trends evaluated at the publication 
versus association level (Figure 5). This is because a single publication can be broadly 
categorised as being about one thing (e.g. metals/metalloids), but actually present multiple 
results (e.g. for five different metals) which are uniquely relevant to the context of chemical 
risk assessment, and the manner in which substances are currently regulated on a single 
chemical-by-chemical basis. Thus, even minimally increasing resolution, as in our evidence 
map, is likely to increase the value of the evidence surveillance exercise for regulatory 
applications (e.g. Wolffe et al, 2019).  
 
Presenting mapped associations as a computationally accessible and queryable output (rather 
than as a static data table within a pdf) also has advantages over traditional scoping methods 
of evidence surveillance. Static data tables or visualizations may be valuable and fit for the 
purpose of identifying trends and specific evidence gaps, but they limit the range of questions 
which can be asked of the collated data - requiring interested users to re-conduct data 
extraction efforts should they wish to explore the presented trends in further detail, or from 
alternate angles. Thus, ensuring that the underlying data is computationally accessible 
expands the utility of evidence surveillance exercises. This, in combination with increased 
resolution meant that we were able to identify evidence gaps in an equivalent manner to 
Sobus et al.’s scoping review (e.g. finding a lack of investigated associations between “PAHs” 
and “cancer”), but were also able to query the data to learn/infer more about the evidence 
landscape. For example, even if completely ignorant to the chemistry of included exposures - 
uncovering the fact that the “Dioxins, Furans, PCBs” group was most frequently studied as a 
mixture of chemicals - and having access to the constituents of those mixtures, allows users 
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to learn something about the potential similarities and/or detection of these chemicals - which 
may be of significance for their regulation.  
 
5.2 Exploring application of a graph-based approach to systematic evidence 
mapping 
Although our mapping exercise only minimally increased the resolution of extracted data, the 
subsequent increase in complexity and connectedness of the underlying data model was 
significant and began to present issues for representation in flat data structures. This can be 
illustrated by comparing the structure of the flat data table which housed the pre-processed 
raw data (Table S2) to the graph data model which stored this data. The flat data table 
contained a combination of expanding rows and columns, where only the authors (as 
producers of the map), are cognizant of the relationships between the attributes and entities 
housed in various rows and columns. Contrastingly, the graph data model (Fig. 1) makes these 
relationships explicit to end-users and maintains referential integrity.  
 
We opted to use Neo4j’s (community edition) graph database implementation for this initial 
exploration of a graph-based approach to evidence-mapping due to its accessibility and the 
availability of resources designed for non-technical audiences to familiarise themselves with 
the graph database (Robinson et al., 2015; Sasaki et al., 2018). Neo4j implements a labelled-
property graph model, whereby nodes can be assigned labels and properties e.g. labels of 
“HealthOutcome”, “SingleChemicalExposure” etc. were applied to nodes in our evidence map, 
and properties of “Title”, “Authors”, “Year” etc. assigned specifically to the publication nodes 
in our evidence map. We found this graph data model amenable to manual evidence mapping 
efforts, utilising labels to facilitate categorising and querying the evidence base. Populating 
and querying the graph was intuitive, but did require some technical knowledge in the form 
of the cypher querying language. This technical knowledge indicates a key barrier to the wider 
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uptake of graph-based approaches for evidence mapping in environmental health. However, 
a growing volume of resources (Robinson et al., 2015; Sasaki et al., 2018), tools designed for 
non-specialists (e.g. Neo4j, 2020) and increasing computational literacy of evidence mappers 
will aide overcoming this barrier.  
 
We found a more severe barrier to the graph-based approach in attempting to balance the 
potential for higher resolution with the limitations set by a manual data extraction process. In 
the initial planning phase of this exercise, we hoped to expand our definition of an 
“association” as “occurring between any two entities for which the results of a statistical 
measure/model of associated were reported” - including assessments between e.g. stratified 
and non-stratified populations, adjusted and non-adjusted models etc. as independent 
associations and extracting detail on the statistical approach, significance and direction of the 
associations. However, this dramatically increased the manual data extraction burden of the 
exercise e.g. Dye et al. (2002) which reports 4 associations in our lower resolution map would 
report 59 associations according to this expanded definition. A lack of sufficient time and 
resources meant that we were unable to pursue such high-resolution mapping manually. This 
challenge is likely reflected by the limited resource availability of chemicals policy workflows. 
This highlights the need for more automated approaches to data screening and especially 
extraction if the full potential of high-resolution graph-based evidence maps are to be 
realised.  
 
Preserving resolution and facilitating automation appears well aligned with the storage of data 
as semantic triples within a knowledge graph, discussed in our previous work (see Wolffe et 
al., 2020). This is because all information expressed with language within a publication can be 
captured as a series of subject-predicate-object triples, where subjects and objects occupy 
nodes of a graph, and predicates form the relationships which connect subjects and objects. 
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The designation of subjects, predicates and objects is dependent on rules and conventions 
inherent to the structure of language - thus mappers need not manually “choose” information 
from a publication for extraction. Instead, all plain text within a publication can be parsed into 
sets of semantic triples using natural language processing (Rusu et al., 2014). Although such 
parsers are available in other fields (e.g. Gangemi et al., 2009) we are unaware of their 
successful application in evidence mapping or environmental health contexts. It can also be 
argued that distilling unstructured text into a series of semantic triples is not a data extraction 
task, but is the data standard to which publications should adhere in the first instance.  
 
However, with higher resolution and automated extraction workflows comes increased 
complexity for graph outputs. Much of this complexity may be noise - i.e. information which 
is irrelevant to the interests of users wishing to query the evidence landscape for a particular 
application. This makes accessing trends within the graph and/or discovering underlying data 
models more challenging than in our lower resolution, manually produced exercise. This is 
where binding data to ontologies is vital for distilling data relevant to a particular domain, and 
for characterising the evidence space around a domain. However, this is still an area of active 
research - and another aspect of the graph-based approach limited by a greater demand for 
technical knowledge.  
 
5.3 Expanding this evidence mapping exercise  
Pending further advances and applications of the automated approaches required to facilitate 
high resolution knowledge graphs, it remains important to continue exploration of graph-
based approaches to evidence mapping as a means of upholding data integrity. To this end, 





While data extraction workflows are still largely manual, ensuring the process is conducted in 
duplicate by two independent mappers will help to protect against human error and improve 
the accuracy and consistency of extracted information. Additionally, expanding the search 
strategy used to find relevant publications e.g. by removing restrictive terms such as those 
relating to specific biomarkers (“urine”, “blood” etc.), and updating the date-range of the 
search to encompass current literature, will ensure a more comprehensive coverage of the 
evidence-landscape within the map. Extracting even minimal additional detail from each of 
the included studies would also serve to increase the resolution and utility of the map. 
Similarly, extracting exposure-exposure associations from the exposure studies (excluded for 
the purposes of this mapping exercise) will begin to facilitate more complex graph queries, 
e.g. where a path from an exposure source such as personal care products can be traversed 
to a health outcome through related biomarkers - even if the exposure source and the health 
outcome were not reported within the same study. However, screening and extracting a 
larger, updated dataset in duplicate will incur the same challenges regarding manual 
workflows and resource availability as discussed above.  
 
Even without further screening or data extraction, there is scope for expanding the utility of 
the evidence map. Incorporating a relevant ontology will help to further categorise and 
organise data, such that the map can be queried against the topics of interest to a particular 
domain (e.g. cancer biology). This will also ensure that the map is interoperable and will 
facilitate the incorporation of data from sources beyond the publications collated in the 
mapping exercise, adding greater contextual value to the interpretation of trends. For 
example, incorporating evidence from environmental monitoring studies into the map of 




There is also scope to better characterise the use (or gaps in the use) of NHANES data by 
developing an ontology derived from the NHANES datasets themselves. A potential workflow 
for the development of such an ontology is briefly outlined in Fig. 6. Incorporating all data 
variables available in the NHANES datasets into an ontology will facilitate the identification of 
specific variables which might be available for analysis but have been under-utilised in studies 
of association. Maintaining relationships between specific variables and the NHANES survey 
cycle in which those variables were studied will facilitate detailed exploration and inferencing 
of how trends have changed over time, e.g. allowing fast identification of whether a sudden 
increase in associations studied for a particular chemical is due to  a corresponding sudden 
availability of data within a new NHANES survey cycle, or whether such trends can be 
attributed to other factors. Ensuring that NHANES variables are related through a hierarchy of 
terms will facilitate further, variably resolved querying of included associations e.g. if 
“Cadmium, blood” and “Cadmium, urine” are categorised as “Cadmium” before 
“metals/metalloids”, trends can be analysed at three levels of resolution. This may be 
particularly useful for chemical substances which are currently grouped in very broad 




Figure 6: Brief outline of a potential workflow for devising a controlled vocabulary 
ontology which describes the availability of data within the NHANES datasets. Variables 
which are more specific to particular survey cycles (e.g. dates) might also be incorporated 




Incorporating health related variables from the NHANES datasets would prove similarly 
beneficial for the resolution of queries and interpretation of identified trends. We noticed that 
the health outcomes reported in many included studies were not explicitly reported as 
NHANES variables, but were defined by authors based on several more specific NHANES 
variables. For example, Muntner et al. (2005) defined “hypertension” as “...based on the 
average of all available blood pressure measurements, hypertension was defined as systolic 
or diastolic blood pressure of at least 140 mm Hg or 90 mm Hg, respectively, and/or self-
reported current use of blood pressure– lowering medication.” Thus, maintaining a link 
between the individual variables within the NHANES datasets which constitute a defined 
health outcome will improve insights into the use of NHANES data, and will allow the 




In this manuscript, we presented an exploration of the implementation of graph-based 
approaches to evidence mapping using a context of relevance to decision-making in 
environmental health, and a dataset accessible to others wishing to learn from, or further 
expand this work. The graph data model is a flexible and intuitive means of maintaining data 
integrity when extracting, storing and querying increasingly complex, higher resolution 
datasets. It has significant potential application for evidence surveillance within regulatory 
workflows - and when coupled with SEM methodology, offers greater transparency and 
reusability than current scoping approaches.  
 
However, our exploration of the application of graphs to current evidence mapping workflows 




1. Although the graph data model is arguably more intuitive than flat, or relational data 
models - graph-based approaches demand a greater level of technical expertise to 
implement. This may present a barrier for evidence mappers who are unfamiliar with 
the programming and querying languages required for successful implementation.  
2. Graphs are capable of upholding referential integrity for complex and highly 
connected datasets and facilitate highly resolved queries. However, the manual 
nature of data extraction within SEM methodology limits the resolution and 
complexity of the datasets to be stored within a graph- preventing graphs from being 
exploited to their full potential.  
 
Research into the automation of evidence synthesis workflows is ongoing (van Altena et al., 
2019; Connor et al., 2019; Marshall & Wallace, 2019) - and will facilitate the production of 
large and informative graph datasets. In the interim, it is vital to continue increasing familiarity 
with graph-based approaches and their associated data standards. Continued research into 
the application of graphs for evidence surveillance will allow independently conducted, 
manual mapping efforts to be amalgamated. This will facilitate a deeper understanding not 
only of the toxicological evidence landscape, but of the methods required to implement 
evidence mapping at scale.   
 
7. Acknowledgements  
 
The authors would like to thank Jon Sobus for helpful correspondence during the formulation 
of this mapping exercise. We also thank Matthew Barnes, senior library assistant at Lancaster 




8. Funding Sources 
TW's PhD is financially supported by the Centre for Global Eco-Innovation (a programme 
funded by the European Regional Development Fund) and Yordas Group, a global consultancy 
in the area of chemical safety, regulations and sustainability. PW’s contribution to the 
manuscript was funded by the Evidence-Based Toxicology Collaboration at Johns Hopkins 
Bloomberg School of Public Health. 
9. Author Contributions 
 
TW established the principle ideas for the mapping exercise. All authors refined the scope of 
the mapping exercise according to resource availability. TW screened studies at full text, 
extracted data, populated and queried the graph database, and wrote the first draft of the 




Ahluwalia, N., Dwyer, J., Terry, A., Moshfegh, A., & Johnson, C. (2016). Update on NHANES 
Dietary Data : Focus on Collection , Release , Analytical Considerations , and Uses to 
Inform Public Policy 1 , 2, (9). https://doi.org/10.3945/an.115.009258.status 
Bell, S., & Edwards, S. (2015). Identification and Prioritization of Relationships between 
Environmental Stressors and Adverse Human Health Impacts, 123(11), 1193–1199. 
Beverly, B. (2019). Abstract 3267: Potential Alternatives to Systematic Review: Evidence 
111 
 
Maps and Scoping Reviews. Retrieved from 
https://www.toxicology.org/events/am/AM2019/program-details.asp 
Brown, N., van Rongen, J., van de Velde, J., & Williams, M. (2019). A Reproduction of the 
Results of Onyike et al. (2003). PsyArXiv, 6–8. 
https://doi.org/https://doi.org/10.31234/osf.io/hbnm9 
CDC. (2001). Blood and Hair Mercury Levels in Young Children and Women of Childbearing 
Age --- United States, 1999. Retrieved from 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5008a2.htm 
Centers for Disease Control and Prevention. (2019a). National Health and Nutrition 
Examination Survey: Overview. https://doi.org/10.4135/9781483346663.n401 
Centers for Disease Control and Prevention. (2019b). National Health and Nutrition 
Examination Survey 1999 – 2014 Survey Content Brochure 1999 – 2014. 
Christensen, K., Sobus, J., Phillips, M., Blessinger, T., Lorber, M., & Tan, Y. (2014). Changes in 
epidemiologic associations with different exposure metrics : A case study of phthalate 
exposure associations with body mass index and waist circumference ☆ , ☆☆. 
Environment International, 73, 66–76. https://doi.org/10.1016/j.envint.2014.07.010 
Connor, A. M. O., Tsafnat, G., Gilbert, S. B., Thayer, K. A., Shemilt, I., Thomas, J., … Wolfe, M. 
S. (2019). Still moving toward automation of the systematic review process : a summary 
of discussions at the third meeting of the International Collaboration for Automation of 
Systematic Reviews ( ICASR ), 1–5. 
Dye, B. A., Hirsch, R., & Brody, D. J. (2002). The Relationship between Blood Lead Levels and 
Periodontal Bone Loss in the United States , 1988 – 1994, 110(10), 997–1002. 
Easthope, T., & Valeriano, L. (2007). Phase Out Persistent, Bioaccumulative or Highly Toxic 
Chemicals. New Solutions, 17(3), 193–207. https://doi.org/10.2190/NS.17.3.d 
112 
 
EPA. (2003). EPA Handbook for Use of Data from the National Health and Nutrition 
Examination Surveys ( NHANES ): A Goldmine of Data for Environmental Health 
Analysis, 1–180. 
Gangemi, A., Presutti, V., Recupero, D. R., Nuzzolese, A. G., & Draicchio, F. (2009). Semantic 
Web Machine Reading with FRED, 1, 1–5. 
Gumbo, D., Clendenning, J., Martius, C., Moombe, K., Grundy, I., Nasi, R., … Petrokofsky, G. 
(2018). How have carbon stocks in central and southern Africa ’ s miombo woodlands 
changed over the last 50 years ? A systematic map of the evidence. Environmental 
Evidence, 1–19. https://doi.org/10.1186/s13750-018-0128-0 
Gupta, P., Goel, A., Lin, J., Sharma, A., Wang, D., & Zadeh, R. (2013). WTF : The Who to 
Follow Service at Twitter, 505–514. 
Hitzler, P. (2012). Facebook Linked Data via the Graph API, 1, 1–6. 
James, K. L., Randall, N. P., & Haddaway, N. R. (2016). A methodology for systematic mapping 
in environmental sciences. Environmental Evidence, 5(1), 7. 
https://doi.org/10.1186/s13750-016-0059-6 
Kobrosly, R. W., Parlett, L. E., Stahlhut, R. W., Barrett, E. S., & Swan, S. H. (2012). 
Socioeconomic factors and phthalate metabolite concentrations among United States 
women of reproductive age. Environmental Research, 115, 11–17. 
https://doi.org/10.1016/j.envres.2012.03.008 
Markowitz, L. E., Hariri, S., Lin, C., Dunne, E. F., Steinau, M., Mcquillan, G., & Unger, E. R. 
(2013). Reduction in Human Papillomavirus ( HPV ) Prevalence Among Young Women 
Following HPV Vaccine Introduction in the United States , National Health and Nutrition 
Examination Surveys , 2003 – 2010, 208, 385–393. https://doi.org/10.1093/infdis/jit192 
Marshall, I. J., & Wallace, B. C. (2019). Toward systematic review automation : a practical 
113 
 
guide to using machine learning tools in research synthesis, 9, 1–10. 
Muntner, P., Menke, A., DeSalvo, K. B., Rabito, F. A., & Batuman, V. (2005). Continued 
Decline in Blood Lead Levels Among Adults in the United States. Archives of Internal 
Medicine, 165. 
Nelson, J. W., Scammell, M. K., Hatch, E. E., & Webster, T. F. (2012). Social disparities in 
exposures to bisphenol A and polyfluoroalkyl chemicals : a cross-sectional study within 
NHANES 2003-2006, 1–15. 
Neo4j. (2019). Neo4j. Retrieved from https://neo4j.com/ 
Neo4j. (2020). Neo4j Bloom. Retrieved from http://neo4j.com/bloom/ 
Pelch, K. E., Reade, A., Wolffe, T. A. M., & Kwiatkowski, C. F. (2019). PFAS health effects 
database: Protocol for a systematic evidence map. Environment International, 
130(May). https://doi.org/10.1016/j.envint.2019.05.045 
Project Jupyter. (2019). Jupyter. Retrieved from https://jupyter.org/ 
Robinson, I., Webber, J., & Eifrem, E. (2015). Graph Databases. O’Reilly. 
https://doi.org/10.1016/B978-0-12-407192-6.00003-0 
Rusu, D., Dali, L., Fortuna, B., Grobelnik, M., & Mladeni, D. (2014). Triplet extraction from 
sentences. 
Sasaki, B. M., Chao, J., Howard, R., Sasaki, B. M., Chao, J., & Howard, R. (2018). Graph 
Databases for Beginners Graph Databases For Beginners. 
Singhal, A. (2012). Introducing the Knowledge Graph: things, not strings. Retrieved from 
https://googleblog.blogspot.com/2012/05/introducing-knowledge-graph-things-
not.html 
Small, N. (2019). The Py2neo v4 Handbook. Retrieved from http://py2neo.org/v4/ 
114 
 
Sobus, J. R., DeWoskin, R. S., Tan, Y. M., Pleil, J. D., Phillips, M. B., George, B. J., … Edwards, S. 
W. (2015). Uses of NHANES biomarker data for chemical risk assessment: Trends, 
challenges, and opportunities. Environmental Health Perspectives, 123(10), 919–927. 
https://doi.org/10.1289/ehp.1409177 
Stone, B. M., & Reynolds, C. R. (2003). Can the National Health and Nutrition Examination 
Survey III ( NHANES III ) data help resolve the controversy over low blood lead levels 
and neuropsychological development in children ?, 18, 219–244. 
https://doi.org/10.1016/S0887-6177(03)00005-2 
Taboureau, O., & Audouze, K. (2017). Human environmental disease network: A 
computational model to assess toxicology of contaminants. Altex, 34(2), 289–300. 
https://doi.org/10.14573/altex.1607201 
Tyrrell, J., Melzer, D., Henley, W., Galloway, T. S., & Osborne, N. J. (2013). Associations 
between socioeconomic status and environmental toxicant concentrations in adults in 
the USA : NHANES 2001 – 2010. Environment International, 59, 328–335. 
https://doi.org/10.1016/j.envint.2013.06.017 
van Altena, A. J., Spijker, R., Olabarriaga, S. D. (2019). Usage of automation tools in 
systematic reviews. Research Synthesis Methods, 10 (1), 72–82. 
https://doi.org/10.1002/jrsm.1335 
Wolffe, T. A. M., Vidler, J., Halsall, C., Hunt, N., & Whaley, P. (2020). A survey of systematic 
evidence mapping practice and the case for knowledge graphs in environmental health 
& toxicology. Manuscript Submitted for Publication. 
Wolffe, T. A. M., Whaley, P., Halsall, C., Rooney, A. A., & Walker, V. R. (2019). Systematic 
evidence maps as a novel tool to support evidence-based decision-making in chemicals 








Evidence-based approaches such as systematic review, which have transformed medical and 
social sciences, have much to offer environmental health. Interest in their uptake, especially 
for chemical risk assessment and regulatory purposes, is growing – and is representative of an 
overall push to reform the resource efficiency, representativeness and rigour in developing 
chemicals policy. These sentiments are increasingly important as the chemicals industry 
continues to grow, and as the availability of data relevant to chemical risk assessment 
exponentially increases.    
However, uptake of systematic review for chemical risk assessment is not without its 
challenges. Some of these challenges are more fundamental to the systematic review process 
(e.g. the need to appropriately manage subjectivity when assessing risk of bias of included 
studies, see Chapter One); while others are specific to regulatory decision-making (e.g. limited 
resource availability and a broader set of information requirements than can be addressed by 
a single systematic review, see Chapter Two); or to environmental health data itself (e.g. 
managing the integrity of highly complex and connected data, see Chapter Three). Facilitating 
uptake of evidence-based approaches to chemical risk assessment requires that these 
challenges are understood and addressed. 
Continuing to develop and communicate best practice for environmental health systematic 
reviews serves to address the challenges associated with accessing the methodology itself. 
This is a key focus for several working groups dedicated to the EBT movement (Johns Hopkins 
Bloomberg School of Public Health, 2019; NTP-OHAT, 2019; UCSF Program on Reproductive 
Health and the Environment, 2019 etc.) who produce comprehensive systematic review 
guidance, training, standards and methodological tools tailored for the environmental health 
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context (e.g. Hoffmann et al., 2017; NTP, 2015; OHAT, 2015; Schaefer & Myers, 2017; 
Woodruff & Sutton, 2014 etc.). Open and constructive dialogue regarding best practice for EH 
SRs may help to establish standards and consensus within the field, or at the least – equip 
stakeholders with the understanding required to critically appraise current evidence synthesis 
practice. Such ongoing communication is an important aspect of the move toward more 
evidence-based approaches to chemical risk assessment, especially as ill-defined systematic 
review practices begin to appear in regulatory frameworks (e.g. Scientific Committee on 
Consumer Safety SCCS, 2019) or as aspects of the methodology adapted for regulatory 
frameworks deviate from best-practice (e.g. the numerical scoring system recommended for 
assessing risk of bias in the EPA’s systematic review methodology for TSCA risk evaluations 
(EPA, 2018)).  
Understanding the needs and limitations of regulatory decision-making is key to devising tools 
and/or workflows which facilitate the uptake of evidence-based approaches. In this thesis, 
systematic evidence mapping is identified as a methodological solution which addresses these 
needs and limitations (see Chapter Two). By providing a much broader overview of the 
evidence-landscape, SEMs facilitate the identification of trends (including issues of emerging 
regulatory concern), on which to focus resources. The computationally accessible and easily 
updated format of SEMs as queryable databases renders them multi-purpose and “re-
useable”, ensuring that any data collated, characterised and stored is available for varied 
present and/or future uses. This creates larger returns on the resources invested when 
developing a SEM. The evidence-surveillance function served by SEMs is an integral 
component of existing regulatory decision-making frameworks – and thus the methodology 
can be more readily incorporated into current chemical risk assessment workflows. Similarly, 
SEMs are able to serve the information retrieval steps of systematic review. Thus, not only do 
SEMs facilitate the formulation of informative (rather than empty) systematic review research 
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questions through identification of research clusters, but they also potentially reduce the 
workload associated with conducting systematic reviews.   
As interest in, and application of, systematic evidence mapping beings to emerge – it is 
important to understand what underpins the utility of the methodology for chemical risk 
assessment and regulatory decision-making. On a fundamental level, systematic evidence 
mapping transforms unstructured, textual data which is heterogeneous and distributed over 
disparate sources – into a single, organised and machine-readable resource. It is this 
accessibility of data which allows trends across vast quantities of evidence to be 
programmatically explored, quickly and efficiently. Thus, ensuring that the data management 
practices of systematic evidence maps do not compromise this accessibility is vital for the 
successful application of the methodology. In this thesis, the familiar, tabular-based data 
management practices of evidence mapping in other fields were found to be poorly suited to 
the complex and highly connected nature of toxicology and environmental health data. The 
rigidity of these data structures was found to compromise data integrity and consequently 
reduced the utility of evidence maps for varied application. The graph data model was 
identified as a flexible alternative, capable of directly storing the relationships between highly 
connected toxicology data (see Chapter Three).  
Modelling toxicology data as a graph, and storing relationships as queryable entities, has 
significant implications for trend-spotting – facilitating complex and highly resolved graph 
queries which traverse patterns of information. These complex queries have the potential to 
move systematic evidence mapping beyond the identification of broad trends such as research 
gaps and research clusters, and toward more highly resolved applications such as the 
identification of adverse outcome pathways (Villeneuve et al., 2018). This may serve to 
facilitate a more predictive (rather than simply proactive) approach to chemical risk 
assessment. However, graph-based technologies are novel and unfamiliar to stakeholders 
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working within environmental health. There is therefore a need to bridge the gap between 
those with expertise in the implementation of graph-based data management, and those with 
expertise in the potential applications of graph-based data management (i.e. regulatory 
decision-making within toxicology and environmental health). Continued exploration and 
communication of the potential gains in data integrity, transparency and interoperability 
offered by the application of graphs within environmental health will serve to increase 
familiarity within the field and resolve the future research required to implement evidence 
mapping at scale (see Chapter Four) - expediting the uptake of resource-efficient evidence-
based methods within chemicals policy and wider environmental health.   
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Future Work  
 
Successfully implementing evidence-based approaches to chemical risk assessment requires 
that the resource burden associated with these approaches is lessened. Whilst systematic 
evidence mapping offers a more resource-efficient framework for pursuing evidence-based 
decision-making - its manual workflow continues to present barriers to wider uptake. Thus, a 
key focus of future work within the field is the development of automated approaches to 
evidence-mapping. 
 
Automation is a topic of increasing interest for evidence synthesis applications, with several 
ongoing research efforts (van Altena et al., 2019; Connor et al., 2019; Marshall & Wallace, 
2019). These efforts have largely manifested as tools which assist the screening and/or 
literature tagging aspects of evidence synthesis workflows and are beginning to appear as 
standard features of review management software (e.g. Evidence Partners, 2019; Sciome, 
2018). Screening literasture for inclusion in a systematic review represents a typical case for 
application of automated approaches. This is because, in addressing specific research 
questions, the inclusion/exclusion criteria for systematic reviews are more clearly and 
specifically defined. Thus, machine learning classifiers are able to learn from a manually 
screened training set where all of the included studies are likely to have very similar features. 
In the field of medicine, incorporating automation tools into the systematic review workflow 
has been reported to reduce the time and workload required to complete a systematic review 
e.g. by 40% for the Rayyan tool (Ouzzani, 2017), among many others.  
 
However, as discussed in this thesis – resolving a specific research question for chemical risk 
assessment applications is more difficult – and the range of potentially included evidence 
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considerably more heterogeneous. Similarly, the inclusion criteria for systematic evidence 
maps are much broader. As systematic evidence mapping is fundamentally concerned with 
making data accessible for querying, the data extraction phase of the methodology is most 
important and demanding. Thus, focusing automation efforts on the screening stage of the 
methodology is insufficient for reducing the manual workload of SEMs. Developing automated 
approaches to data extraction, which extend beyond the simple identification of key words 
and toward the consideration of context, is therefore a challenge on which to focus future 
research.  
 
However, it can be argued that the issue of data accessibility which systematic evidence 
mapping targets, is not a challenge for machine learning, but is an issue concerning data 
standards. Ensuring that environmental health evidence is published in a machine-readable 
format (rather than as unstructured text) in the first instance will alleviate the need to 
manually process and store data in a machine accessible format. Similar issues can be found 
motivating the Semantic Web movement (Berners-Lee et al., 2001), which fundamentally 
strives to make unstructured data published on the web machine-accessible – allowing for 
greater connectivity and interoperability. A variety of tools have emerged from this 
movement, including: the resource description framework (RDF) data standard (Manola & 
Miller, 2004), in which data are stored as a graph of semantic triples (see Chapter Three); the 
SPARQL Protocol and RDF Query Language (SPARQL) for querying data stored in RDF format 
(The W3C SPARQL Working Group, 2013); and linked open data libraries (e.g. DBpedia, 2020), 
which allow RDF datasets to be linked through semantic triples to other datasets for greater 
contextual value. Exploring and/or exploiting these tools for evidence mapping applications 
and understanding the overlap/applicability of the Semantic Web movement to the EBT 




Once data are machine-readable, evidence mapping approaches can move away from data 
extraction and focus on deriving value from accessible data. Modelling, characterising and 
querying data will become the key focus for automation efforts, resolving the “signal” for a 
particular research application from what will become a considerably “noisy” computationally 
accessible and interconnected evidence landscape. Facilitating automated approaches to 
querying or deriving value from accessible data requires implementing graph-based controlled 
vocabulary ontologies which organise data for applications within a particular domain (see 
Chapter Three). Such ontologies also form a key aspect of the Semantic Web toolkit. More 
established applications of ontologies for querying and inferencing over graphs of data can be 
found in the pharmaceutical industry (Samwald et al., 2011; Wild et al., 2012; Yankulov, 2019), 
and domain-specific ontologies available for biological fields e.g. (Ashburner et al., 2000; 
National Center for Biomedical Ontology, 2019). These use cases represent valuable learning 
opportunities for evidence-based approaches to chemical risk assessment and risk 
management decision-making. Future work within this area will require the development of 
toxicological ontologies which are relevant to regulatory workflows (Hardy et al., 2012). This 
represents a largely manual, consensus-building exercise and reiterates the importance of 
continued communication of evidence-based methods within chemicals policy.  
 
In the interim, the true value of pursuing these avenues of future research can be explored 
and refined by conducting slightly more narrowly focused evidence mapping exercises within 
environmental health and toxicology, in which the utility of the methodology can still be 
demonstrated and developed without exceeding resource availability. Producing evidence 
maps which can be incorporated directly into chemical risk assessment workflows will 
promote interest and uptake of the methodology, as well as resolve further issues in need of 
future research e.g. the development of user interfaces for evidence maps which are both fit-
for-purpose and accessible to chemical risk assessors, decision-makers and/or the public. 
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the methodology – providing much-needed “case studies”. These exemplar evidence-maps 





Abelkop, A. D. K., & Graham, J. (2014). Regulation of Chemical Risks: Lessons for TSCA 
Reform from Canada and the European Union. SSRN Electronic Journal. 
https://doi.org/10.2139/ssrn.2499309 
Aggarwal, C. C., & Wang, H. (2010). Managing and Mining Graph Data (Vol. 40). Springer. 
https://doi.org/10.1007/978-1-4419-6045-0 
Ahluwalia, N., Dwyer, J., Terry, A., Moshfegh, A., & Johnson, C. (2016). Update on NHANES 
Dietary Data : Focus on Collection , Release , Analytical Considerations , and Uses to Inform 
Public Policy 1 , 2, (9). https://doi.org/10.3945/an.115.009258.status 
Aiassa, E., Higgins, J. P. T., Frampton, G. K., Greiner, M., Afonso, A., Amzal, B., … Verloo, D. 
(2015). Applicability and Feasibility of Systematic Review for Performing Evidence-Based Risk 
Assessment in Food and Feed Safety. Critical Reviews in Food Science and Nutrition, 55(7), 
1026–1034. https://doi.org/10.1080/10408398.2013.769933 
Amec Foster Wheeler Environment & Infrastructure UK Limited. (2017). A study to gather 
insights on the drivers, barriers, costs and benefits for updating REACH registration and CLP 
notification dossiers. 
Applegate, J. S. (2008). Synthesizing TSCA and REACH: Practical principles for chemical 
regulation reform. Ecology Law Quarterly, 35(4), 721–769. 
ArangoDB. (2019). Graphs and ArangoDB. Retrieved from 
https://www.arangodb.com/arangodb-training-center/graphs/ 
Armijo-Olivo, S., Stiles, C. R., Hagen, N. A., Biondo, P. D., & Cummings, G. G. (2012). 
Assessment of study quality for systematic reviews: A comparison of the Cochrane 
125 
 
Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality 
Assessment Tool: Methodological research. Journal of Evaluation in Clinical Practice, 18(1), 
12–18. https://doi.org/10.1111/j.1365-2753.2010.01516.x 
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., … Rubin, Gerald 
M. Sherlock, G. (2000). Gene Ontology: tool for the unification of biology. Nature Genetics, 
25(1), 25–29. https://doi.org/10.1038/75556.Gene 
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., … Rubin, Gerald 
M. Sherlock, G. (2000). The Gene Ontology Consortium, Michael Ashburner1, Catherine A. 
Ball3, Judith A. Blake4, David Botstein3, Heather Butler1, J. Michael Cherry3, Allan P. Davis4, 
Kara Dolinski3, Selina S. Dwight3, Janan T. Eppig4, Midori A. Harris3, David P. Hill4, Laurie Is. 
Nature Genetics, 25(1), 25–29. https://doi.org/10.1038/75556.Gene 
Baker, N., Boobis, A., Burgoon, L., Carney, E., Currie, R., Fritsche, E., … Daston, G. (2018). 
Building a developmental toxicity ontology. Birth Defects Research, 110(6), 502–518. 
https://doi.org/10.1002/bdr2.1189 
Balk, E., Bonis, P., Moskowitz, H., Schmid, C. H., Ioannidis, J. P. A., Wang, C., & Lau, J. (2002). 
Correlation of QualityMeasures With Estimates of Treatment Effect inMeta-analyses of 
Randomized Controlled Trials. JAMA, 287(22), 2973–2982. 
Barra Caracciolo, A., de Donato, G., Finizio, A., Grenni, P., Santoro, S., & Petrangeli, A. B. 
(2013). A New Online Database on Chemicals in Accordance with REACH Regulation. Human 
and Ecological Risk Assessment, 19(6), 1682–1699. 
https://doi.org/10.1080/10807039.2012.708271 
Bell, S., & Edwards, S. (2015). Identification and Prioritization of Relationships between 
Environmental Stressors and Adverse Human Health Impacts, 123(11), 1193–1199. 
126 
 
Berkman, N. D., Lina Santaguida, M. P., Viswanathan, M., & Morton, S. C. (2014). The 
Empirical Evidence of Bias in Trials Measuring Treatment Differences. Retrieved from 
https://www.ncbi.nlm.nih.gov/books/NBK253181/pdf/Bookshelf_NBK253181.pdf 
Berners-Lee, T., Hendler, J., & Lassila, O. (2001). The Semantic Web. Scientific American, 
284(5), 34–43. 
Bernes, C., Bullock, J. M., Jakobsson, S., Rundlöf, M., Verheyen, K., & Lindborg, R. (2017). 
How are biodiversity and dispersal of species affected by the management of roadsides? A 
systematic map. Environmental Evidence, 6(1), 1–16. https://doi.org/10.1186/s13750-017-
0103-1 
Bernes, C., Jonsson, B. U., Junninen, K., Lõhmus, A., Macdonald, E., Müller, J., & Sandström, J. 
(2015). What is the impact of active management on biodiversity in boreal and temperate 
forests set aside for conservation or restoration? A systematic map. Environmental Evidence, 
4(1), 1–22. https://doi.org/10.1186/s13750-015-0050-7 
Beronius, A., & Hanberg, A. (2017). SciRAP workshop report Bridging the gap between 
academic research and Workshop report : “ Bridging the gap between academic research 
and. Retrieved from http://www.diva-portal.org/smash/get/diva2:1074866/FULLTEXT02.pdf 
Beronius, A., & Vandenberg, L. N. (2015). Using systematic reviews for hazard and risk 
assessment of endocrine disrupting chemicals. Reviews in Endocrine and Metabolic 
Disorders, 16(4), 273–287. https://doi.org/10.1007/s11154-016-9334-7 
Beverly, B. (2019). Abstract 3267: Potential Alternatives to Systematic Review: Evidence 
Maps and Scoping Reviews. Retrieved from 
https://www.toxicology.org/events/am/AM2019/program-details.asp 
Blaha, M. R., Premerlani, W. J., & Rumbaligh, J. E. (1988). Relational database design using an 
object-oriented methodology. Computing Practices, 31(4). 
127 
 
Bolden, A. L., Rochester, J. R., Schultz, K., & Kwiatkowski, C. F. (2017). Polycyclic aromatic 
hydrocarbons and female reproductive health: A scoping review. Reproductive Toxicology, 
73, 61–74. https://doi.org/10.1016/j.reprotox.2017.07.012 
Bolvig, J., Juhl, C. B., Boutron, I., Tugwell, P., Ghogomu, E. A. T., Pardo, J. P., … Christensen, R. 
(2018). Some Cochrane risk-of-bias items are not important in osteoarthritis trials: a meta-
epidemiological study based on Cochrane reviews. Journal of Clinical Epidemiology, 95, 128–
136. https://doi.org/10.1016/j.jclinepi.2017.11.026 
Borah, R., Brown, A. W., Capers, P. L., & Kaiser, K. A. (2017). Analysis of the time and workers 
needed to conduct systematic reviews of medical interventions using data from the 
PROSPERO registry. BMJ Open, 7(2), 1–7. https://doi.org/10.1136/bmjopen-2016-012545 
Brown, N., van Rongen, J., van de Velde, J., & Williams, M. (2019). A Reproduction of the 
Results of Onyike et al. (2003). PsyArXiv, 6–8. 
https://doi.org/https://doi.org/10.31234/osf.io/hbnm9 
Brown, V. J. (2003). REACHing for Chemical Safety. Environmental Health Perspectives, 
111(14). 
Buxton, L. (2017). Echa clarifies Brexit impacts on UK, EU regulatory obligations. Retrieved 
October 25, 2017, from https://chemicalwatch.com/59534/echa-clarifies-brexit-impacts-on-
uk-eu-regulatory-obligations 
CAMARADES-NC3Rs. (2019). Preclinical Systematic Review & Meta-analysis Facility (SyRF). 
Retrieved February 6, 2019, from http://syrf.org.uk/ 
Castelltort, A., & Laurent, A. (2016). Rogue behavior detection in NoSQL graph databases. 




CDC. (2001). Blood and Hair Mercury Levels in Young Children and Women of Childbearing 
Age --- United States, 1999. Retrieved from 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5008a2.htm 
Centers for Disease Control and Prevention. (2019a). National Health and Nutrition 
Examination Survey: Overview. https://doi.org/10.4135/9781483346663.n401 
Centers for Disease Control and Prevention. (2019b). National Health and Nutrition 
Examination Survey 1999 – 2014 Survey Content Brochure 1999 – 2014. 
Chalmers, I., Hedges, L., & Cooper, H. (2002). A brief history of research synthesis. Evaluation 
& the Health …, 25(1), 12–37. https://doi.org/10.1177/0163278702025001003 
Cheng, S. H., Macleod, K., Ahlroth, S., Onder, S., Perge, E., Shyamsundar, P., … Miller, D. C. 
(2019). A systematic map of evidence on the contribution of forests to poverty alleviation. 
Environmental Evidence, 1–22. https://doi.org/10.1186/s13750-019-0148-4 
Christensen, K., Sobus, J., Phillips, M., Blessinger, T., Lorber, M., & Tan, Y. (2014). Changes in 
epidemiologic associations with different exposure metrics : A case study of phthalate 
exposure associations with body mass index and waist circumference ☆ , ☆☆. Environment 
International, 73, 66–76. https://doi.org/10.1016/j.envint.2014.07.010 
Clapton, J., Rutter, D., & Sharif, N. (2009). SCIE Systematic mapping guidance April 2009. 
Retrieved from https://www.scie.org.uk/publications/researchresources/rr03.pdf 
Cochrane Community. (2019). MECIR Manual: Assessing risk of bias in included studies (C52-





Cochrane Methods Group. (2017). Assessing Risk of Bias in Included Studies. Retrieved 
November 3, 2017, from http://methods.cochrane.org/bias/assessing-risk-bias-included-
studies 
Collaboration for Environmental Evidence. (2019a). CEE Meetings. Retrieved September 20, 
2007, from https://www.environmentalevidence.org/meetings 
Collaboration for Environmental Evidence. (2019b). Completed Reviews. Retrieved from 
http://www.environmentalevidence.org/completed-reviews 
Collaboration for Environmental Evidence. (2019c). Environmental Evidence: Systematic Map 
Submission Guidelines. Retrieved from 
https://environmentalevidencejournal.biomedcentral.com/submission-guidelines/preparing-
your-manuscript/systematic-map 
Commission of the European Communities. (1998). Report on the operation of DIRECTIVE 
67/548/EEC, DIRECTIVE 88/379/EEC, REGULATION (EEC) 793/93 AND DIRECTIVE 761769/EEC. 
Commission of the European Communities. (2001). White Paper: Strategy for a future 
chemicals policy (Vol. 13). https://doi.org/10.1007/BF03038641 
Connor, A. M. O., Tsafnat, G., Gilbert, S. B., Thayer, K. A., Shemilt, I., Thomas, J., … Wolfe, M. 
S. (2019). Still moving toward automation of the systematic review process : a summary of 
discussions at the third meeting of the International Collaboration for Automation of 
Systematic Reviews ( ICASR ), 1–5. 
Cooper, G. S., Lunn, R. M., Ågerstrand, M., Glenn, B. S., Kraft, A. D., Luke, A. M., & Ratcliffe, J. 
M. (2016). Study sensitivity: Evaluating the ability to detect effects in systematic reviews of 




Covidence. (2019). Covidence. Retrieved January 14, 2019, from 
https://www.covidence.org/home 
Cresswell, C. J., Wilcox, A., Randall, N. P., & Cunningham, H. M. (2018). What specific plant 
traits support ecosystem services such as pollination, bio-control and water quality 
protection in temperate climates? A systematic map. Environmental Evidence, 7(1), 1–13. 
https://doi.org/10.1186/s13750-018-0120-8 
Crossley, N. A., Sena, E., Goehler, J., Horn, J., Van Der Worp, B., Bath, P. M. W., … Dirnagl, U. 
(2008). Empirical evidence of bias in the design of experimental stroke studies: A 
metaepidemiologic approach. Stroke, 39(3), 929–934. 
https://doi.org/10.1161/STROKEAHA.107.498725 
Datawrapper GmbH. (2019). Datawrapper. Retrieved from https://www.datawrapper.de/ 
DBpedia. (2020). DBpedia. Retrieved from http://wiki.dbpedia.org/ 
De Vet, H. C. W., De Bie, R. A., Van Der Heijden, G. J. M. G., Verhagen, A. P., Sijpkes, P., & 
Knipschild, P. G. (1997). Systematic reviews on the basis of methodological criteria. 
Physiotherapy, 83(6), 284–289. https://doi.org/10.1016/S0031-9406(05)66175-5 
Dechartres, A., Trinquart, L., Faber, T., & Ravaud, P. (2016). Empirical evaluation of which 
trial characteristics are associated with treatment effect estimates. Journal of Clinical 
Epidemiology, 77, 24–37. https://doi.org/10.1016/j.jclinepi.2016.04.005 
Deeks, J. J., Dinnes, J., D’Amico, R., Sowden, A. J., Sakarovitch, C., Song, F., … European 
Carotid Surgery Trial Collaborative Group. (2003). Evaluating non-randomised intervention 
studies. Health Technology Assessment (Winchester, England), 7(27). https://doi.org/96-26-
99 [pii] 
Dillon, T., Chang, E., Hadzic, M., & Wongthongtham, P. (2008). Differentiating conceptual 
modelling from data modelling, knowledge modelling and ontology modelling and a notation 
131 
 
for ontology modelling. Conferences in Research and Practice in Information Technology 
Series, 79. 
Ding, W., Liang, P., Tang, A., & Van Vliet, H. (2014). Knowledge-based approaches in software 
documentation: A systematic literature review. Information and Software Technology, 56(6), 
545–567. https://doi.org/10.1016/j.infsof.2014.01.008 
Downs, S. H., & Black, N. (1998). The feasibility of creating a checklist for the assessment of 
the methodological quality both of randomised and non-randomised studies of health care 
interventions. Journal of Epidemiology and Community Health, 52(6), 377–384. 
https://doi.org/10.1136/jech.52.6.377 
Dye, B. A., Hirsch, R., & Brody, D. J. (2002). The Relationship between Blood Lead Levels and 
Periodontal Bone Loss in the United States , 1988 – 1994, 110(10), 997–1002. 
Easthope, T., & Valeriano, L. (2007). Phase Out Persistent, Bioaccumulative or Highly Toxic 
Chemicals. New Solutions, 17(3), 193–207. https://doi.org/10.2190/NS.17.3.d 
ECHA. (2016). Practical guide How to use alternatives to animal testing to fulfil your 
information requirements for REACH registration. 
ECHA. (2019a). REACH registration results. Retrieved from https://echa.europa.eu/reach-
registrations-since-2008 
ECHA. (2019b). Weight of evidence. Retrieved from 
https://echa.europa.eu/support/registration/how-to-avoid-unnecessary-testing-on-
animals/weight-of-evidence 
Eckley, N., & Selin, H. (2004). All talk, little action: Precaution and European chemicals 




Edwards, S. W., Tan, Y.-M., Villeneuve, D. L., Meek, M. E., & McQueen, C. A. (2015). Adverse 
Outcome Pathways--Organizing Toxicological Information to Improve Decision Making. 
Journal of Pharmacology and Experimental Therapeutics, 356(1), 170–181. 
https://doi.org/10.1124/jpet.115.228239 
Egeghy, P. P., Judson, R., Gangwal, S., Mosher, S., Smith, D., Vail, J., & Cohen Hubal, E. A. 
(2012). The exposure data landscape for manufactured chemicals. Science of the Total 
Environment, 414, 159–166. https://doi.org/10.1016/j.scitotenv.2011.10.046 
Elmasri, R., & Navathe, S. B. (2016). The Relational Data Model and Relational Database 
Constraints. Fundamentals of Database Systems, 150–152. 
EPA. (2003). EPA Handbook for Use of Data from the National Health and Nutrition 
Examination Surveys ( NHANES ): A Goldmine of Data for Environmental Health Analysis, 1–
180. 
EPA. (2018). Application of Systematic Review in TSCA Risk Evaluations, 1–247. Retrieved 
from https://www.epa.gov/sites/production/files/2018-
06/documents/final_application_of_sr_in_tsca_05-31-18.pdf 
EPA’s Office of Pollution Prevention and Toxics. (1998). Chemical Hazard Data Availability 
Study - What Do We Really Know About the Safety of High Production Volume Chemicals? 
Retrieved from https://noharm-uscanada.org/sites/default/files/documents-
files/915/Chemical_Hazard_Data_Availability_Study_1998.pdf 
European Chemicals Agency. (2011). Guidance on information requirements and chemical 
safety assessment Chapter R . 4: Evaluation of available information. Retrieved from 
https://echa.europa.eu/documents/10162/13643/information_requirements_r4_en.pdf 




European Chemicals Agency. (2017a). Guidance on information requirements and chemical 
safety assessment: QSARs and grouping of chemicals. Guidance for the Implementation of 
REACH, 134. https://doi.org/10.2823/43472 
European Chemicals Agency. (2017b). Study finds companies lack incentives for updating 
their REACH registrations. Retrieved November 8, 2018, from https://echa.europa.eu/-
/study-finds-companies-lack-incentives-for-updating-their-reach-registrations 
European Chemicals Agency. (2018a). Information Requirements. Retrieved November 9, 
2018, from https://echa.europa.eu/regulations/reach/registration/information-
requirements 
European Chemicals Agency. (2018b). Strategy for gathering your data. Retrieved November 
9, 2018, from https://echa.europa.eu/support/registration/strategy-for-gathering-your-data 
European Comission. (2007). REACH In Brief. https://doi.org/10.1067/j.cpsurg.2007.09.005 
European Comission. (2016). REACH. Retrieved October 25, 2017, from 
http://ec.europa.eu/environment/chemicals/reach/reach_en.htm 
European Environment Agency. (2013). Late lessons from early warnings: science, 
precaution, innovation — European Environment Agency. Retrieved from 
http://www.eea.europa.eu/publications/late-lessons-2 
European Food Safety Authority. (2010). Application of systematic review methodology to 
food and feed safety assessments to support decision making 1 EFSA Guidance for those 
carrying out systematic reviews, 8(6). https://doi.org/10.2903/j.efsa.2010.1637. 




Gangemi, A., Presutti, V., Recupero, D. R., Nuzzolese, A. G., & Draicchio, F. (2009). Semantic 
Web Machine Reading with FRED, 1, 1–5. 
Garg, A. X., Hackam, D., & Tonelli, M. (2008). Systematic review and meta-analysis: When 
one study is just not enough. Clinical Journal of the American Society of Nephrology, 3(1), 
253–260. https://doi.org/10.2215/CJN.01430307 
Ghrab, A., Romero, O., Skhiri, S., Vaisman, A., & Zimányi, E. (2016). GRAD: On Graph 
Database Modeling. Retrieved from http://arxiv.org/abs/1602.00503 
Giraudeau, B., Higgins, J. P. T., Tavernier, E., & Trinquart, L. (2016). Sample size calculation 
for meta-epidemiological studies. Statistics in Medicine, 35(2), 239–250. 
https://doi.org/10.1002/sim.6627 
Glasziou, P., Djulbegovic, B., & Burls, A. (2006). Are systematic reviews more cost-effective 
than randomised trials? Lancet, 367(9528), 2057–2058. https://doi.org/10.1016/S0140-
6736(06)68919-8 
Goldacre, B. (2013). Bad Pharma: How Medicine is Broken, and How We Can Fix It. 
HarperCollins. 
Golden, R., Doull, J., Waddell, W., & Mandel, J. (2003). Potential Human Cancer Risks from 
Exposure to PCBs: A Tale of Two Evaluations. Critical Reviews in Toxicology, 33(5), 543–580. 
https://doi.org/10.1080/10408440390242414 
Grant, M. J., & Booth, A. (2009). A typology of reviews: An analysis of 14 review types and 
associated methodologies. Health Information and Libraries Journal, 26(2), 91–108. 
https://doi.org/10.1111/j.1471-1842.2009.00848.x 
Greenland, S., & O’Rourke, K. (2001). On the bias produced by quality scores in meta-




Groenwold, R. H. H., & Rovers, M. M. (2010). The Catch-22 of appraisals on the quality of 
observational studies. Journal of Clinical Epidemiology, 63(10), 1059–1060. 
https://doi.org/10.1016/j.jclinepi.2010.04.013 
Gumbo, D., Clendenning, J., Martius, C., Moombe, K., Grundy, I., Nasi, R., … Petrokofsky, G. 
(2018). How have carbon stocks in central and southern Africa ’ s miombo woodlands 
changed over the last 50 years ? A systematic map of the evidence. Environmental Evidence, 
1–19. https://doi.org/10.1186/s13750-018-0128-0 
Gupta, P., Goel, A., Lin, J., Sharma, A., Wang, D., & Zadeh, R. (2013). WTF : The Who to 
Follow Service at Twitter, 505–514. 
Guyatt, G., Cairns, J., Churchill, D., Cook, D., Haynes, B., Hirsh, J., … Tugwell, P. (1992). 
Evidence-Based Medicine A New Approach to Teaching the Practice of Medicine. JAMA. 
https://doi.org/10.1001/jama.1992.03490170092032 
Haddaway, N. R., & Westgate, M. J. (2018). Predicting the time needed for environmental 
systematic reviews and systematic maps. Conservation Biology, 0(0), 1–10. 
https://doi.org/10.1111/cobi.13231 
Haddaway, N. R., Bernes, C., Jonsson, B.-G., & Hedlund, K. (2016). The benefits of systematic 
mapping to evidence-based environmental management. Ambio, 45(5), 613–620. 
https://doi.org/10.1007/s13280-016-0773-x 
Haddaway, N. R., Brown, C., Eales, J., Eggers, S., Josefsson, J., Kronvang, B., … Uusi-Kämppä, J. 
(2018). The multifunctional roles of vegetated strips around and within agricultural fields. 
Environmental Evidence, 7(1), 1–43. https://doi.org/10.1186/s13750-018-0126-2 
Haddaway, N. R., Hedlund, K., Jackson, L. E., Kätterer, T., Lugato, E., Thomsen, I. K., … 
Söderström, B. (2015). What are the effects of agricultural management on soil organic 
136 
 
carbon in boreo-temperate systems? Environmental Evidence, 4(1), 1–29. 
https://doi.org/10.1186/s13750-015-0049-0 
Haddaway, N. R., Macura, B., Whaley, P., & Pullin, A. S. (2018). ROSES RepOrting standards 
for Systematic Evidence Syntheses : pro forma , flow ‑ diagram and descriptive summary of 
the plan and conduct of environmental systematic reviews and systematic maps. 
Environmental Evidence, 4–11. https://doi.org/10.1186/s13750-018-0121-7 
Haddaway, N. R., Styles, D., & Pullin, A. S. (2014). Evidence on the environmental impacts of 
farm land abandonment in high altitude/mountain regions: A systematic map. Environmental 
Evidence, 3(1), 1–19. https://doi.org/10.1186/2047-2382-3-17 
Haddaway, N., & Crowe, S. (editors). (2018). Stakeholder engagement in environmental 
evidence synthesis. Retrieved from 
http://www.eviem.se/Documents/projekt/2018/SRbookAll.pdf 
Hardy, B., Apic, G., Carthew, P., Clark, D., Cook, D., Dix, I., … Yang, C. (2012). Toxicology 
ontology perspectives. Altex, 29(2), 139–156. 
Hartling, L., Ospina, M., Liang, Y., Dryden, D., Hooton, N., Krebs Seida, J., & Klassen, T. (2009). 
Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. 
BMJ (Clinical Research Ed.), 339, 1–6. https://doi.org/10.1136/bmj.b4012 
Hartung, T. (2009). Toxicology for the twenty-first century. Nature. 460, 208-212. 
https://doi.org/10.1038/460208a 
Have, C. T., & Jensen, L. J. (2013). Databases and ontologies Are graph databases ready for 
bioinformatics ?, 29(24), 3107–3108. https://doi.org/10.1093/bioinformatics/btt549 




Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, … JAC, S. (2011). The 
Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. British Medical 
Journal, 343, 889–893. https://doi.org/doi: 10.1136/bmj.d5928 
Higgins J.P.T., Green, S. (editors). (2011). Cochrane Handbook for Systematic Reviews of 
Interventions (Version 5.1.0). 
Higgins, J.P.T., Green, S. (2009). Cochrane Handbook for Systematic Reviews of Interventions 
(Version 5.0.2). 
Hoffmann, S., Hartung, T. (2006). Toward an evidence-based toxicology. Human & 
Experimental Toxicology, 25 , 497–513. 
Hoffmann, S., de Vries, R. B. M., Stephens, M. L., Beck, N. B., Dirven, H. A. A. M., Fowle, J. R., 
… Tsaioun, K. (2017). A primer on systematic reviews in toxicology. Archives of Toxicology, 
91(7), 2551–2575. https://doi.org/10.1007/s00204-017-1980-3 
Hooijmans, C. R., Rovers, M., de Vries, R. B., Leenaars, M., & Ritskes-Hoitinga, M. (2012). An 
initiative to facilitate well-informed decision-making in laboratory animal research: Report of 
the First International Symposium on Systematic Reviews in Laboratory Animal Science. 
Laboratory Animals, 46(4), 356–357. https://doi.org/10.1258/la.2012.012052 
Hooker, R. C. (1997). The rise and rise of evidence-based medicine [20]. Lancet, 349(9061), 
1329–1330. https://doi.org/10.1016/S0140-6736(05)62552-4 
Hróbjartsson, A., Emanuelsson, F., Thomsen, A. S. S., Hilden, J., & Brorson, S. (2014). Bias due 
to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients 
to blind and nonblind sub-studies. International Journal of Epidemiology, 43(4), 1272–1283. 
https://doi.org/10.1093/ije/dyu115 















Ingre-Khans, E., Ågerstrand, M., Beronius, A., & Rudén, C. (2016). Transparency of chemical 
risk assessment data under REACH. Environmental Science: Processes and Impacts, 18(12), 
1508–1518. https://doi.org/10.1039/c6em00389c 
Ingre-Khans, E., Ågerstrand, M., Beronius, A., & Rudén, C. (2019). Reliability and relevance 
evaluations of REACH data. Toxicology Research, 8(1), 46–56. 
https://doi.org/10.1039/c8tx00216a 
Innvaer, S., Vist, G., Trommald, M., & Oxman, A. (2002). Review article Health policy-makers ’ 
perceptions of their use of evidence : a systematic review. Journal of Health Services 
Research & Policy, 7(4), 239–244. https://doi.org/10.1258/135581902320432778 
Jadad, A. R., & Enkin, M. W. (2008). Randomized Controlled Trials: Questions, Answers, and 





Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & 
McQuay, H. J. (1996). Assessing the quality of reports of randomized clinical trials: Is blinding 
necessary? Controlled Clinical Trials, 17(1), 1–12. https://doi.org/10.1016/0197-
2456(95)00134-4 
James, K. L., Randall, N. P., & Haddaway, N. R. (2016). A methodology for systematic mapping 
in environmental sciences. Environmental Evidence, 5(1), 7. https://doi.org/10.1186/s13750-
016-0059-6 
Janković, S., Mladenović, S., Mladenović, D., Vesković, S., & Glavić, D. (2018). Schema on read 
modeling approach as a basis of big data analytics integration in EIS. Enterprise Information 
Systems, 12(8–9), 1180–1201. https://doi.org/10.1080/17517575.2018.1462404 
Johns Hopkins Bloomberg School of Public Health. (2019). Evidence-Based Toxicology 
Collaboration. Retrieved from http://ebtox.org/ 
Juni, P., Altman, D. G., & Egger, M. (2001). Systematic reviews in health care: Assessing the 
quality of controlled clinical trials. BMJ, 323(7303), 42–46. 
https://doi.org/10.1136/bmj.323.7303.42 
Jüni, P., Witschi, A., Bloch, R., & Egger, M. (1999). The hazards of scoring the quality of 
clinical trials for meta-analysis. JAMA : The Journal of the American Medical Association, 
282(11), 1054–1060. https://doi.org/10.1001/jama.282.11.1054 
Karp, P. D. (1996). Database links are a foundation for interoperability. Trends in 
Biotechnology, 14(8), 273–279. https://doi.org/10.1016/0167-7799(96)10044-5 
Kelly, S. E., Moher, D., & Clifford, T. J. (2016). Quality of conduct and reporting in rapid 
reviews: An exploration of compliance with PRISMA and AMSTAR guidelines. Systematic 
Reviews, 5(1), 1–19. https://doi.org/10.1186/s13643-016-0258-9 
140 
 
Kleppmann, M. (2017). Designing Data-Intensive Applications. O’Reilly Media, Inc. Retrieved 
from https://www.oreilly.com/library/view/designing-data-intensive-
applications/9781491903063/ 
Klimisch, H.-J., Andreae, M., & Tillmann, U. (1997). A Systematic Approach for Evaluating the 
Quality of Experimental Toxicological and Ecotoxicological Data. Regulatory Toxicology and 
Pharmacology, 25(1), 1–5. https://doi.org/10.1006/rtph.1996.1076 
Kobrosly, R. W., Parlett, L. E., Stahlhut, R. W., Barrett, E. S., & Swan, S. H. (2012). 
Socioeconomic factors and phthalate metabolite concentrations among United States 
women of reproductive age. Environmental Research, 115, 11–17. 
https://doi.org/10.1016/j.envres.2012.03.008 
Koch, L., & Ashford, N. A. (2006). Rethinking the role of information in chemicals policy: 
Implications for TSCA and REACH. Journal of Cleaner Production, 14(1), 31–46. 
https://doi.org/10.1016/j.jclepro.2005.06.003 
Krauth, D., Woodruff, T. J., & Bero, L. (2013). Instruments for assessing risk of bias and other 
methodological criteria of published animal studies: A systematic review. Environmental 
Health Perspectives, 121(9), 985–992. https://doi.org/10.1289/ehp.1206389 
Lau, J., Rothstein, H., & Stewart, G. (2013). History & progress of meta-analysis (Handbook of 
Meta-analysis in Ecology and Evolution). Princeton University Press. Retrieved from 
https://books.google.co.uk/books?id=Zh3GNd9M1oUC&printsec=frontcover&source=gbs_g
e_summary_r&cad=0 
Lefebvre, C. (1994). The Cochrane Collaboration: the role of the UK Cochrane Centre in 
identifying the evidence. Health Libraries Review, 11, 235–242. 
Leisher, C., Temsah, G., Booker, F., Day, M., Samberg, L., Prosnitz, D., … Wilkie, D. (2016). 
Does the gender composition of forest and fishery management groups affect resource 
141 
 
governance and conservation outcomes? A systematic map. Environmental Evidence, 5(1), 
1–10. https://doi.org/10.1186/s13750-016-0057-8 
Lewis, K. A., Tzilivakis, J., Warner, D. J., & Green, A. (2016). An international database for 
pesticide risk assessments and management. Human and Ecological Risk Assessment, 22(4), 
1050–1064. https://doi.org/10.1080/10807039.2015.1133242 
Liu, Z. H., & Gawlick, D. (2015). Management of Flexible Schema Data in RDBMSs - 
Opportunities and Limitations for NoSQL -. 
Lundh, A., & Gøtzsche, P. C. (2008). Recommendations by Cochrane Review Groups for 
assessment of the risk of bias in studies. BMC Medical Research Methodology, 8, 22. 
https://doi.org/10.1186/1471-2288-8-22 
Lyndon, M. (1989). Information Economics and Chemical Toxicity : Designing Laws to 
Produce and Use Data. Michigan Law Review, 87(7), 1795–1861. 
Macleod, M. R., Lawson McLean, A., Kyriakopoulou, A., Serghiou, S., de Wilde, A., Sherratt, 
N., … Sena, E. S. (2015). Risk of Bias in Reports of In Vivo Research: A Focus for Improvement. 
PLoS Biology, 13(10), 1–12. https://doi.org/10.1371/journal.pbio.1002273 
Macura, B., Secco, L., & Pullin, A. S. (2015). What evidence exists on the impact of 
governance type on the conservation effectiveness of forest protected areas? Knowledge 
base and evidence gaps. Environmental Evidence, 4(1). https://doi.org/10.1186/s13750-015-
0051-6 
Mandrioli, D., Schlünssen, V., Ádám, B., Cohen, R. A., Colosio, C., Chen, W., … Scheepers, P. T. 
J. (2018). WHO/ILO work-related burden of disease and injury: Protocol for systematic 
reviews of occupational exposure to dusts and/or fibres and of the effect of occupational 




Manola, F., & Miller, E. (2004). RDF Primer, 1–107. 
Mara-eves, A. O., Thomas, J., Mcnaught, J., Miwa, M., & Ananiadou, S. (2015). Using text 
mining for study identification in systematic reviews: a systematic review of current 
approaches. Systematic Reviews, 1–22. https://doi.org/10.1186/2046-4053-4-5 
Markowitz, L. E., Hariri, S., Lin, C., Dunne, E. F., Steinau, M., Mcquillan, G., & Unger, E. R. 
(2013). Reduction in Human Papillomavirus ( HPV ) Prevalence Among Young Women 
Following HPV Vaccine Introduction in the United States , National Health and Nutrition 
Examination Surveys , 2003 – 2010, 208, 385–393. https://doi.org/10.1093/infdis/jit192 
Marshall, I. J., & Wallace, B. C. (2019). Toward systematic review automation : a practical 
guide to using machine learning tools in research synthesis, 9, 1–10. 
Marshall, I., Marshall, R., Wallace, B., Brassey, J., & Thomas, J. (2018). Rapid reviews may 
produce different results to systematic reviews: a meta-epidemiological study. Journal of 
Clinical Epidemiology. https://doi.org/10.1016/j.jclinepi.2018.12.015 
Martin, O. V., Geueke, B., Groh, K. J., Chevrier, J., Fini, J.-B., Houlihan, J., … Muncke, J. (2018). 
Protocol for a systematic map of the evidence of migrating and extractable chemicals from 
food contact articles. https://doi.org/10.5281/zenodo.2525277 
Martin, P., Bladier, C., Meek, B., Bruyere, O., Feinblatt, E., Touvier, M., … Makowski, D. 
(2018). Weight of evidence for hazard identification: A critical review of the literature. 
Environmental Health Perspectives, 126(7), 1–15. https://doi.org/10.1289/EHP3067 
McKinnon, M. C., Cheng, S. H., Dupre, S., Edmond, J., Garside, R., Glew, L., … Woodhouse, E. 
(2016). What are the effects of nature conservation on human well-being? A systematic map 




McMichael, A. J. (1976). Standardized Mortality Ratios and the “Healthy Worker Effect”: 




Moja, L. P., Telaro, E., D’Amico, R., Moschetti, I., Coe, L., & Liberati, A. (2005). Assessment of 
methodological quality of primary studies by systematic reviews: results of the metaquality 
cross sectional study. Bmj, 330(7499), 1053. https://doi.org/10.1136/bmj.38414.515938.8F 
Morgan, M. G. (2014). Use (and abuse) of expert elicitation in support of decision making for 
public policy. Proceedings of the National Academy of Sciences of the United States of 
America, 111(20), 7176–7184. https://doi.org/10.1073/pnas.1319946111 
Morgan, R. L., Thayer, K. A., Bero, L., Bruce, N., Falck-Ytter, Y., Ghersi, D., … Schünemann, H. 
J. (2016). GRADE: Assessing the quality of evidence in environmental and occupational 
health. Environment International, 92–93, 611–616. 
https://doi.org/10.1016/j.envint.2016.01.004 
Muntner, P., Menke, A., DeSalvo, K. B., Rabito, F. A., & Batuman, V. (2005). Continued 
Decline in Blood Lead Levels Among Adults in the United States. Archives of Internal 
Medicine, 165. 
National Academy of Sciences. (1983). Risk Assessment in the Federal Government: 
Managing the Process. Washington, DC: National Academy Press. 
https://doi.org/10.17226/366 




National Centre for the Replacement Refinement & Reduction of Animals in Research. 
(2018). The 3Rs. Retrieved November 8, 2018, from https://www.nc3rs.org.uk/the-3rs 
National Institute for Health Research. (2018). PROSPERO - International prospective register 
of systematic reviews. Retrieved December 31, 2018, from 
https://www.crd.york.ac.uk/prospero/ 
Neaves, L. E., Eales, J., Whitlock, R., Hollingsworth, P. M., Burke, T., & Pullin, A. S. (2015). The 
fitness consequences of inbreeding in natural populations and their implications for species 
conservation - A systematic map. Environmental Evidence, 4(1), 1–17. 
https://doi.org/10.1186/s13750-015-0031-x 
Nelson, J. W., Scammell, M. K., Hatch, E. E., & Webster, T. F. (2012). Social disparities in 
exposures to bisphenol A and polyfluoroalkyl chemicals : a cross-sectional study within 
NHANES 2003-2006, 1–15. 
Neo4j. (2019). Neo4j. Retrieved from https://neo4j.com/ 
Neo4j. (2020). Neo4j Bloom. Retrieved from http://neo4j.com/bloom/ 
Noy, N. F., & Klein, M. (2004). Ontology Evolution: Not the Same as Schema Evolution. 
Knowledge and Information Systems, 6(4), 428–440. https://doi.org/10.1007/s10115-003-
0137-2 
NTP. (2015). Handbook for conducting a literature-based health assessment using OHAT 
approach for systemic review and evidence integration, 1–98. Retrieved from 
https://ntp.niehs.nih.gov/ntp/ohat/pubs/handbookjan2015_508.pdf 




O’Connor, S. R., Tully, M. A., Ryan, B., Bradley, J. M., Baxter, G. D., & McDonough, S. M. 
(2015). Failure of a numerical quality assessment scale to identify potential risk of bias in a 
systematic review: a comparison study. BMC Research Notes, 8, 224. 
https://doi.org/10.1186/s13104-015-1181-1 
OHAT. (2015). OHAT Risk of Bias Rating Tool for Human and Animal Studies, 1–37. Retrieved 
from https://ntp.niehs.nih.gov/ntp/ohat/pubs/riskofbiastool_508.pdf 
Oliver, S., Dickson, K. (2016). Policy-relevant systematic reviews to strengthen health 
systems: Models and mechanisms to support their production. Evidence and Policy, 12(2), 
235–259. https://doi.org/10.1332/174426415X14399963605641 
Ontotext. (2019a). Ontotext GraphDB. Retrieved from 
https://www.ontotext.com/products/graphdb/ 
Ontotext. (2019b). What is a Knowledge Graph? Retrieved from 
https://www.ontotext.com/knowledgehub/fundamentals/what-is-a-knowledge-graph/ 
Ontotext. (2019c). What is Inference? Retrieved from 
https://www.ontotext.com/knowledgehub/fundamentals/what-is-inference/ 
Ouzzani, M. (2017). Rayyan — a web and mobile app for systematic reviews. Systematic 
Reviews, (2016), 1–10. https://doi.org/10.1186/s13643-016-0384-4 
Papathanasopoulou, E., Queirós, A. M., Beaumont, N., Hooper, T., & Nunes, J. (2016). What 
evidence exists on the local impacts of energy systems on marine ecosystem services: a 
systematic map. Environmental Evidence, 5(1), 1–12. https://doi.org/10.1186/s13750-016-
0075-6 
Pavlopoulos, G. A., Secrier, M., Moschopoulos, C. N., Soldatos, T. G., Kossida, S., Aerts, J., … 
Bagos, P. G. (2011). Using graph theory to analyze biological networks, 1–27. 
146 
 
Pega, F., Norris, S. L., Backes, C., Bero, L. A., Descatha, A., Gagliardi, D., Godderis, L., Loney, 
T., Modenese, A., Morgan, R. L., Pachito, D., Paulo, M. B. S., Scheepers, P. T. J., Schlünssen, 
V., Sgargi, D., Silbergeld, E. K., Sørensen, K., Sutton, P., Tenkate, T., … Mandrioli, D. (2020). 
RoB-SPEO : A tool for assessing risk of bias in studies estimating the prevalence of exposure 
to occupational risk factors from the WHO / ILO Joint Estimates of the Work-related Burden 
of Disease and Injury. Environment International, 135, 
https://doi.org/10.1016/j.envint.2019.105039 
Pelch, K. E., Bolden, A. L., & Kwiatkowski, C. F. (2019). Environmental Chemicals and Autism: 
A Scoping Review of the Human and Animal Research. Environmental Health Perspectives, 
127(4), 46001. https://doi.org/10.1289/EHP4386 
Pelch, K. E., Reade, A., Wolffe, T. A. M., & Kwiatkowski, C. F. (2019). PFAS health effects 
database: Protocol for a systematic evidence map. Environment International, 130. 
https://doi.org/10.1016/j.envint.2019.05.045 
Pool, Robert, Rusch, E. (2014). Identifying and Reducing Environmental Health Risks of 
Chemicals in Our Society: Workshop Summary. Washington, DC: The National Academies 
Press. 
Project Jupyter. (2019). Jupyter. Retrieved from https://jupyter.org/ 
QlikTech International AB. (2019). Qlik Sense. Retrieved from 
https://www.qlik.com/us/products/qlik-sense 
Randall, N. P., & James, K. L. (2012). The effectiveness of integrated farm management, 
organic farming and agri-environment schemes for conserving biodiversity in temperate 




Randall, N. P., Donnison, L. M., Lewis, P. J., & James, K. L. (2015). How effective are on-farm 
mitigation measures for delivering an improved water environment? A systematic map. 
Environmental Evidence, 4(1), 18. https://doi.org/10.1186/s13750-015-0044-5 
Reynen, E., Robson, R., Ivory, J., Hwee, J., Straus, S. E., Pham, B., & Tricco, A. C. (2018). A 
retrospective comparison of systematic reviews with same-topic rapid reviews. Journal of 
Clinical Epidemiology, 96, 23–34. https://doi.org/10.1016/j.jclinepi.2017.12.001 
Rhomberg, L. R., Goodman, J. E., Bailey, L. A., Prueitt, R. L., Beck, N. B., Bevan, C., … Becker, 
R. A. (2013). A survey of frameworks for best practices in weight-of-evidence analyses. 
Critical Reviews in Toxicology, 43(9), 753–784. 
https://doi.org/10.3109/10408444.2013.832727 
Robinson, I., Webber, J., & Eifrem, E. (2015). Graph Databases. O’Reilly. 
https://doi.org/10.1016/B978-0-12-407192-6.00003-0 
Rooney, A. A., Boyles, A. L., Wolfe, M. S., Bucher, J. R., & Thayer, K. A. (2014). Systematic 
review and evidence integration for literature-based environmental health science 
assessments. Environmental Health Perspectives, 122(7), 711–718. 
https://doi.org/10.1289/ehp.1307972 
Rooney, A. A., Cooper, G. S., Jahnke, G. D., Lam, J., Morgan, R. L., Boyles, A. L., Ratcliffe, J. M., 
Kraft, A. D., Schünemann, H. J., Schwingl, P., Walker, T. D., Thayer, K. A., & Lunn, R. M. 
(2016). How credible are the study results? Evaluating and applying internal validity tools to 
literature-based assessments of environmental health hazards. Environment International, 
92–93, 617–629. https://doi.org/10.1016/j.envint.2016.01.005 




Rudén, C. (2001a). Interpretations of primary carcinogenicity data in 29 trichloroethylene risk 
assessments. Toxicology, 169(3), 209–225. https://doi.org/10.1016/S0300-483X(01)00525-X 
Rudén, C. (2001b). The use and evaluation of primary data in 29 trichloroethylene carcinogen 
risk assessments. Regulatory Toxicology and Pharmacology, 34(1), 3–16. 
https://doi.org/10.1006/rtph.2001.1482 
Rus, I., & Lindvall, M. (2002). Knowledge management in software engineering. IEEE 
Software, 19(3), 26–38. https://doi.org/10.1109/MS.2002.1003450 
Rusu, D., Dali, L., Fortuna, B., Grobelnik, M., & Mladeni, D. (2014). Triplet extraction from 
sentences. 
Sadowski, G., & Rathle, P. (2014). Fraud Detection: Discovering Connections with Graph 
Databases. Neo Technology, 17. 
Samuel, G. O., Hoffmann, S., Wright, R. A., Lalu, M. M., Patlewicz, G., Becker, R. A., … 
Stephens, M. L. (2016). Guidance on assessing the methodological and reporting quality of 
toxicologically relevant studies: A scoping review. Environment International, 92–93, 630–
646. https://doi.org/10.1016/j.envint.2016.03.010 
Samwald, M., Jentzsch, A., Bouton, C., Kallesøe, C. S., Willighagen, E., Hajagos, J., … Stephens, 
S. (2011). Linked Open drug data for pharmaceutical research and development. Journal of 
Cheminformatics, 3(5), 1–6. https://doi.org/10.1186/1758-2946-3-19 
Sanderson, S., Tatt, I. D., & Higgins, J. P. T. (2007). Tools for assessing quality and 
susceptibility to bias in observational studies in epidemiology: A systematic review and 
annotated bibliography. International Journal of Epidemiology, 36(3), 666–676. 
https://doi.org/10.1093/ije/dym018 
Sasaki, B. M., Chao, J., Howard, R., Sasaki, B. M., Chao, J., & Howard, R. (2018). Graph 
Databases for Beginners Graph Databases For Beginners. 
149 
 
Schaafsma, G., Kroese, E. D., Tielemans, E. L. J. P., Van de Sandt, J. J. M., & Van Leeuwen, C. J. 
(2009). REACH, non-testing approaches and the urgent need for a change in mind set. 
Regulatory Toxicology and Pharmacology, 53(1), 70–80. 
https://doi.org/10.1016/j.yrtph.2008.11.003 
Schaefer, H. R., & Myers, J. L. (2017). Guidelines for performing systematic reviews in the 
development of toxicity factors. Regulatory Toxicology and Pharmacology, 91, 124–141. 
https://doi.org/10.1016/j.yrtph.2017.10.008 
Schmidt, C. W. (2016). TSCA 2.0 - A New Era in Chemical Risk Management. Environmental 
Health Perspectives, 124(10), 182–186. 
Schneider, K., Schwarz, M., Burkholder, I., Kopp-Schneider, A., Edler, L., Kinsner-Ovaskainen, 
A., … Hoffmann, S. (2009). “ToxRTool”, a new tool to assess the reliability of toxicological 
data. Toxicology Letters, 189(2), 138–144. https://doi.org/10.1016/j.toxlet.2009.05.013 
Schoeters, G. (2010). The reach perspective: Toward a new concept of toxicity testing. 
Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 13(2–4), 232–241. 
https://doi.org/10.1080/10937404.2010.483938 
Schultz, T. W., Cronin, M. T. D., Walker, J. D., & Aptula, A. O. (2003). Quantitative structure-
activity relationships (QSARS) in toxicology: A historical perspective. Journal of Molecular 
Structure: THEOCHEM, 622(1–2), 1–22. https://doi.org/10.1016/S0166-1280(02)00614-0 
Schwarzman, M., & Wilson, M. (2009). New science for chemicals policy. Science, 326(5956), 
1065–1066. https://doi.org/10.1126/science.1177537 
Science for Nature and People Partnership Evidence-Based Conservation working group, 




Scientific Committee on Consumer Safety SCCS. (2019). Guidance on the Safety Assessment 
of nanomaterials in cosmetics. https://doi.org/10.2773/ISBN 
Sciome. (2018). SWIFT-Review. Retrieved January 14, 2019, from 
https://www.sciome.com/swift-review/ 
Segaran, T., Evans, C., & Taylor, J. (2009). Programming the Semantic Web: Traditional Data-
Modeling Methods. O’Reilly. 
Sexton, K., & Hattis, D. (2007). Assessing cumulative health risks from exposure to 
environmental mixtures - Three fundamental questions. Environmental Health Perspectives, 
115(5), 825–832. https://doi.org/10.1289/ehp.9333 
Shamliyan, T., Kane, R. L., & Dickinson, S. (2010). A systematic review of tools used to assess 
the quality of observational studies that examine incidence or prevalence and risk factors for 
diseases. Journal of Clinical Epidemiology, 63(10), 1061–1070. 
https://doi.org/10.1016/j.jclinepi.2010.04.014 
Silbergeld, E. K., Mandrioli, D., & Cranor, C. F. (2015). Regulating Chemicals: Law, Science, 
and the Unbearable Burdens of Regulation. Annual Review of Public Health, 36(1), 175–191. 
https://doi.org/10.1146/annurev-publhealth-031914-122654 
Singhal, A. (2012). Introducing the Knowledge Graph: things, not strings. Retrieved from 
https://googleblog.blogspot.com/2012/05/introducing-knowledge-graph-things-not.html 
Small, N. (2019). The Py2neo v4 Handbook. Retrieved from http://py2neo.org/v4/ 
Sobus, J. R., DeWoskin, R. S., Tan, Y. M., Pleil, J. D., Phillips, M. B., George, B. J., … Edwards, S. 
W. (2015). Uses of NHANES biomarker data for chemical risk assessment: Trends, challenges, 




Sola, P., Cerutti, P. O., Zhou, W., Gautier, D., Iiyama, M., Shure, J., … Shepherd, G. (2017). The 
environmental, socioeconomic, and health impacts of woodfuel value chains in Sub-Saharan 
Africa: A systematic map. Environmental Evidence, 6(1), 1–16. 
https://doi.org/10.1186/s13750-017-0082-2 
Solomon, K. R., Wilks, M. F., Bachman, A., Boobis, A., Moretto, A., Pastoor, T. P., … Embry, M. 
R. (2016). Problem formulation for risk assessment of combined exposures to chemicals and 
other stressors in humans. Critical Reviews in Toxicology, 46(10), 835–844. 
https://doi.org/10.1080/10408444.2016.1211617 
Stardog. (2019). Stardog. Retrieved from https://www.stardog.com/ 
Stone, B. M., & Reynolds, C. R. (2003). Can the National Health and Nutrition Examination 
Survey III ( NHANES III ) data help resolve the controversy over low blood lead levels and 
neuropsychological development in children ?, 18, 219–244. https://doi.org/10.1016/S0887-
6177(03)00005-2 





Taboureau, O., & Audouze, K. (2017). Human environmental disease network: A 
computational model to assess toxicology of contaminants. Altex, 34(2), 289–300. 
https://doi.org/10.14573/altex.1607201 
The Cochrane Collaboration. (2019). Cochrane UK. Retrieved from http://uk.cochrane.org/ 




The Endocrine Disruption Exchange. (2019b). The Endocrine Disruption Exchange. Retrieved 
from http://endocrinedisruption.org/ 
The National Academies of Sciences. (2017). Application of Systematic Review Methods in an 
Overall Strategy for Evaluating Low-Dose Toxicity from Endocrine Active Chemicals. 
Washington, DC: The National Academies Press. https://doi.org/10.17226/24758 
The W3C SPARQL Working Group. (2013). SPARQL 1.1 Overview. Retrieved from 
https://www.w3.org/TR/sparql11-overview/ 
Thomas J, Brunton J, G. S. (2010). EPPI-Reviewer 4.0: software for research synthesis. 
London: Social Science Research Unit, Institute of Education, University of London. Retrieved 
from http://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3299#Research impact 
Thorn, J. P. R., Friedman, R., Benz, D., Willis, K. J., & Petrokofsky, G. (2016). What evidence 
exists for the effectiveness of on-farm conservation land management strategies for 
preserving ecosystem services in developing countries? A systematic map. Environmental 
Evidence, 5(1), 1–29. https://doi.org/10.1186/s13750-016-0064-9 
Tyrrell, J., Melzer, D., Henley, W., Galloway, T. S., & Osborne, N. J. (2013). Associations 
between socioeconomic status and environmental toxicant concentrations in adults in the 
USA : NHANES 2001 – 2010 ☆. Environment International, 59, 328–335. 
https://doi.org/10.1016/j.envint.2013.06.017 
U.S. National Library of Medicine. (2016). Unified Medical Language System (UMLS). 
Retrieved December 31, 2018, from https://www.nlm.nih.gov/research/umls/ 
UCSF Program on Reproductive Health and the Environment. (2019). Navigation Guide. 
Retrieved from https://prhe.ucsf.edu/navigation-guide 
153 
 
United States Environmental Protection Agency. (2016). The Frank R. Lautenberg chemical 
safety for the 21st century act. Retrieved from https://www.epa.gov/assessing-and-
managing-chemicals-under-tsca/frank-r-lautenberg-chemical-safety-21st-century-act 
van Altena, A. J., Spijker, R., Olabarriaga, S. D. (2019). Usage of automation tools in 
systematic reviews. Research Synthesis Methods, 10 (1), 72–82. 
https://doi.org/10.1002/jrsm.1335 
van Leeuwen, K., Schultz, T. W., Henry, T., Diderich, B., & Veith, G. D. (2009). Using chemical 
categories to fill data gaps in hazard assessment. SAR and QSAR in Environmental Research, 
20(3–4), 207–220. https://doi.org/10.1080/10629360902949179 
Vandenberg, L. N., Ågerstrand, M., Beronius, A., Beausoleil, C., Bergman, Å., Bero, L. A., … 
Rudén, C. (2016). A proposed framework for the systematic review and integrated 
assessment (SYRINA) of endocrine disrupting chemicals. Environmental Health: A Global 
Access Science Source, 15(1), 1–19. https://doi.org/10.1186/s12940-016-0156-6 
Villeneuve, D. L., Angrish, M. M., Fortin, M. C., Katsiadaki, I., Leonard, M., Margiotta-Casaluci, 
L., … Knapen, D. (2018). Adverse outcome pathway networks II: Network analytics. 
Environmental Toxicology and Chemistry, 37(6), 1734–1748. 
https://doi.org/10.1002/etc.4124 
Vink, S. R., Mikkers, J., Bouwman, T., Marquart, H., & Kroese, E. D. (2010). Use of read-across 
and tiered exposure assessment in risk assessment under REACH – A case study on a phase-
in substance. Regulatory Toxicology and Pharmacology, 58, 64–71. 
https://doi.org/10.1016/j.yrtph.2010.04.004 
Vinken, M., Whelan, M., & Rogiers, V. (2014). Adverse outcome pathways: Hype or hope? 
Archives of Toxicology, 88(1), 1–2. https://doi.org/10.1007/s00204-013-1093-6 
154 
 
Walker, V. R., Boyles, A. L., Pelch, K. E., Holmgren, S. D., Shapiro, A. J., Blystone, C. R., … 
Rooney, A. A. (2018). Human and animal evidence of potential transgenerational inheritance 
of health effects: An evidence map and state-of-the-science evaluation. Environment 
International, 115, 48–69. https://doi.org/10.1016/j.envint.2017.12.032 
Weaver, J., Tarjan, P. (2012). Facebook Linked Data via the Graph API, IOS Press, 1, 1–6. 
Webber, J. (2018). Powering Real-Time Recommendations with Graph Database Technology. 
Wells, G.A., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P. (2014). The 
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-
analyses. Retrieved from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp 
Whaley, P., Halsall, C. (2016). Assuring high-quality evidence reviews for chemical risk 
assessment: Five lessons from guest editing the first environmental health journal special 
issue dedicated to systematic review. Environment International, 92–93, 553–555. 
https://doi.org/10.1016/j.envint.2016.04.016 
Whaley, P., Halsall, C., Ågerstrand, M., Aiassa, E., Benford, D., Bilotta, G., … Taylor, D. (2016). 
Implementing systematic review techniques in chemical risk assessment: Challenges, 
opportunities and recommendations. Environment International, 92–93, 556–564. 
https://doi.org/10.1016/j.envint.2015.11.002 
Wild, D. J., Ding, Y., Sheth, A. P., Harland, L., Gifford, E. M., & Lajiness, M. S. (2012). Systems 
chemical biology and the Semantic Web: What they mean for the future of drug discovery 
research. Drug Discovery Today, 17(9–10), 469–474. 
https://doi.org/10.1016/j.drudis.2011.12.019 
Wolffe, T. A. M., Vidler, J., Halsall, C., Hunt, N., & Whaley, P. (2020). A survey of systematic 
evidence mapping practice and the case for knowledge graphs in environmental health & 
toxicology. Toxicological Sciences, 175 (1), 35-49.  https://doi.org/10.1093/toxsci/kfaa025 
155 
 
Wolffe, T. A. M., Whaley, P., Halsall, C., Rooney, A. A., & Walker, V. R. (2019). Systematic 
evidence maps as a novel tool to support evidence-based decision-making in chemicals 
policy and risk management. Environment International, 130, 
https://doi.org/10.1016/j.envint.2019.05.065 
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Juni, P., Altman, D. G., … Sterne, J. A. C. (2008). 
Empirical evidence of bias in treatment effect estimates in controlled trials with different 
interventions and outcomes: meta-epidemiological study. BMJ, 336(7644), 601–605. 
https://doi.org/10.1136/bmj.39465.451748.AD 
Woodruff, T. J., & Sutton, P. (2011). An evidence-based medicine methodology to bridge the 
gap between clinical and environmental health sciences. Health Affairs, 30(5), 931–937. 
https://doi.org/10.1377/hlthaff.2010.1219 
Woodruff, T. J., & Sutton, P. (2014). The navigation guide systematic review methodology: A 
rigorous and transparent method for translating environmental health science into better 
health outcomes. Environmental Health Perspectives, 122(10), 1007–1014. 
https://doi.org/10.1289/ehp.1307175 
World Health Organization. (2019). Framework for use of Systematic Review methods in 
chemical risk assessment – authors meeting. Retrieved from 
http://who.int/ipcs/events/SRmeeting_US/en/ 
Yankulov, M. (2019). Semantic Search for Smart Data Discovery in the Pharma Industry. 
Retrieved from http://ontotext.com/blog/semantic-search-for-smart-data-discovery-in-the-
pharma-industry/ 







Appendix: PFAS health effects database: Protocol for a systematic 
evidence map 
 
The research presented in this Appendix was published in the journal Environment International in 





























PFAS Health Effects Database: A Protocol for a Systematic Evidence Map 
Authors: Katherine Pelch, Anna Reade, Taylor Wolffe, Carol Kwiatkowski 
 
1.0. Appendix 1. Search strings for PubMed 




#1 375-22-4[rn] OR PFBA[tw] OR "Perfluorobutyric acid"[nm] OR Perfluorobutanoic[tw] OR 
Heptafluorobutanoic[tw] OR Heptafluorobutyric[tw] OR heptaflurorbutyric[tw] OR 
Perfluorobutyric[tw] OR "Heptafluoro-1-butanoic"[tw] OR Perfluoropropanecarboxylic[tw] OR 
"heptafluoro-butanoic"[tw] OR "Heptafluoro-n-butyric"[tw] OR Heptafluorobutyricacid[tw] OR (c4 
[tw] AND perfluorinated [tw]) 
841 
#2 2706-90-3[rn] OR PFPeA[tw] OR "Perfluoropentanoic acid"[nm] OR Perfluoropentanoic[tw] OR 
Perfluorovaleric[tw] OR Nonafluoropentanoic[tw] OR Nonafluorovaleric[tw] OR "n-
Perfluoropentanoic"[tw] OR "Perfluoro-n-pentanoic"[tw] OR "Nonafluoro-valeric"[tw] OR (c5 [tw] 
AND perfluorinated [tw]) 
160 
#3 307-24-4[rn] OR PFHxA[tw] OR "Perfluorohexanoic acid"[nm] OR Perfluorohexanoic[tw] OR 
"Perfluoro-hexanoic"[tw] OR "Perfluoro hexanoate"[tw] OR "IPC-PFFA-6"[tw] OR "undecafluoro-
hexanoic"[tw] OR "Undecafluoro-1-hexanoic"[tw] OR Undecafluorohexanoic[tw] OR (c6 [tw] AND 
perfluorinated [tw]) 
313 
#4 375-85-9[rn] OR 20109-59-5[rn] OR 6130-43-4[rn] OR PFHpA[tw] OR "Perfluoroheptanoic acid"[nm] 
OR Perfluoroheptanoic[tw] OR Perfluoroheptanoicacid[tw] OR Perfluoroheptanoate[tw] OR 
Tridecafluoroheptanoic[tw] OR "Perfluoro-n-heptanoic"[tw] OR Perfluoroenanthic[tw] OR 
"tridecafluoro-heptanoic"[tw] OR "Tridecafluoro-1-heptanoic"[tw] OR "n-perfluoroheptanoic"[tw] 
OR Tridecafluoroenanthic[tw] OR (c7 [tw] AND perfluorinated [tw]) 
245 
#5 375-95-1[rn] OR 4149-60-4[rn] OR PFNA[tw] OR "perfluorononanoic acid"[nm] OR 
perfluorononanoic[tw] OR "Perfluoro-n-nonanoic"[tw] OR Perfluornonansaeure[tw] OR 
"Perfluorononan-1-oic"[tw] OR Perfluoropelargonic[tw] OR Heptadecafluorononanoic[tw] OR 
Heptadecafluornonansaeure[tw] OR "heptadecafluoro-nonanoic"[tw] OR 
Heptadecafluoropelargonic[tw] OR "n-Heptadecafluorononanoic"[tw] OR "heptadecafluoro-n-
nonanoic"[tw] OR (c9 [tw] AND perfluorinated [tw]) 
888 
#6 335-76-2[rn] OR PFDA[tw] OR "Perfluorodecanoic Acid"[nm] OR Perfluorodecanoic[tw] OR 
Nonadecafluorodecanoic[tw] OR Ndfda[tw] OR "Perfluoro-N-decanoic"[tw] OR perfluorocaprylic[tw] 
OR "Nonadecafluoro-n-decanoic"[tw] OR Perfluorocapric[tw] OR "n-perfluorodecanoic"[tw] OR (c10 
[tw] AND perfluorinated [tw]) 
543 
#7 2058-94-8[rn] OR PFUnA[tw] OR "Perfluoroundecanoic Acid"[nm] OR Perfluoroundecanoic[tw] OR 
heneicosafluoroundecanoic[tw] OR "Perfluoro-n-undecanoic"[tw] OR "heneicosafluoro-
undecanoic"[tw] OR "C11-PFA"[tw] OR (c11 [tw] AND perfluorinated [tw]) 
222 
#8 307-55-1[rn] OR PFDoA[tw] OR "Perfluorododecanoic Acid"[nm] OR Perfluorododecanoic[tw] OR 




Dodecanoic"[tw] OR "n-perfluorododecanoic"[tw] OR (c12 [tw] AND perfluorinated [tw]) 
#9 72629-94-8[rn] OR PFTrDA[tw] OR "perfluorotridecanoic acid"[nm] OR perfluorotridecanoic[tw] OR 
Pentacosafluorotridecanoic[tw] OR "Pentacosafluoro-tridecanoic"[tw] OR (c13[tw] AND 
perfluorinated [tw]) 
65 
#10 376-06-7[rn] OR PFTeA[tw] OR PFTA[tw] OR "perfluorotetradecanoic acid"[nm] OR 
"perfluoromyristic acid"[nm] OR perfluorotetradecanoic[tw] OR Heptacosafluorotetradecanoic[tw] 
OR perfluoromyristic[tw] OR "heptacosafluoro-tetradecanoic acid"[tw] OR (c14 [tw] AND 
perfluorinated [tw]) 
92 
#11 375-73-5[rn] OR 59933-66-3[rn] OR 29420-49-3[rn] OR 68259-10-9[rn] OR 45187-15-3[rn] OR 
PFBS[tw] OR PFBuS[tw] OR "Eftop FBSA"[tw] OR "nonafluorobutane-1-sulfonic acid"[nm] OR 
"Perfluorobutanesulfonic acid"[nm] OR "1-Butanesulfonic acid, 1,1,2,2,3,3,4,4,4-nonafluoro-"[tw] 
OR "1-Butanesulfonic acid, nonafluoro-"[tw] OR "1-Perfluorobutanesulfonic acid"[tw] OR "1-
Perfluorobutanesulfonic"[tw] OR "1,1,2,2,3,3,4,4,4-Nonafluoro-1-butanesulfonic acid"[tw] OR 
"1,1,2,2,3,3,4,4,4-Nonafluorobutane-1-sulphonic acid"[tw] OR "Nonafluoro-1-butanesulfonic 
acid"[tw] OR "nonafluoro-1-butanesulfonic"[tw] OR "nonafluoro-butanesulfonic acid"[tw] OR 
"nonafluorobutane sulfonic"[tw] OR "nonafluorobutane-1-sulfonic"[tw] OR 
"Nonafluorobutanesulfonic acid"[tw] OR "nonafluorobutane-1-sulphonic"[tw] OR "pentyl 
perfluorobutanoate"[tw] OR "Perfluoro-1-butanesulfonate"[tw] OR "perfluoro-1-
butanesulfonic"[tw] OR "perfluorobutane sulfonate"[tw] OR "Perfluorobutane sulfonic acid"[tw] OR 
"perfluorobutane sulfonic"[tw] OR "Perfluorobutanesulfonate"[tw] OR "Perfluorobutanesulfonic 
acid"[tw] OR "perfluorobutyl sulfonic"[tw] OR "Perfluorobutylsulfonate"[tw] OR "perfluorobutane-1-
sulfonic"[tw] OR FC-98[tw] OR Nonaflate[tw] OR nonafluorobutanesulfonic[tw] OR 
nonafluorobutanesulphonic[tw] OR perfluorobutanesulphonic[tw]  
328 
#12 2706-91-4[rn] OR PFPeS[tw] OR "perfluoropentanesulfonic acid"[nm] OR 
perfluoropentanesulfonic[tw] OR "perfluoropentane-1-sulphonic"[tw] OR "Perfluoropentane-1-
sulfonic"[tw] OR "1-Pentanesulfonic"[tw] OR "perfluoropentane sulfonic"[tw] OR "Undecafluoro-1-
pentanesulfonic"[tw] OR "undecafluoropentane-1-sulfonic"[tw] 
54 
#13 355-46-4[rn] OR 3871-99-6[rn] OR 68259-08-5[rn] OR pfhxs[tw] OR "Perfluorohexanesulfonic 
Acid"[nm] OR "Perfluorohexane sulfonic"[tw] OR "Perfluorohexane-1-sulphonic"[tw] OR 




#14 375-92-8[rn] OR 60270-55-5[rn] OR PFHpS[tw] OR "Perfluoroheptanesulfonic acid"[nm] OR 
Perfluoroheptanesulfonic[tw] OR "Perfluoroheptane sulfonic"[tw] OR "Pentadecafluoro-1-
heptanesulfonic"[tw] OR "pentadecafluoroheptane-1-sulfonic"[tw] 
26 
#15 68259-12-1[rn] OR 17202-41-4[rn] OR PFNS[tw] OR "Perfluorononanesulfonic acid"[nm] OR 
Perfluorononanesulfonic[tw] OR "Nonadecafluoro-1-nonanesulfonic"[tw] OR "nonadecafluoro-1-
Nonanesulfonic"[tw] 
38 
#16 335-77-3[rn] OR 67906-42-7[rn] OR PFDS[tw] OR "Perfluorodecane sulfonic acid"[nm] OR 
"Perfluorodecane sulfonic"[tw] OR "Perfluorodecane sulphonic"[tw] OR 
henicosafluorodecanesulphonicacid[tw] OR perfluordecansulfonsaure[tw] OR "Perfluorodecane 
sulfonate"[tw] OR "henicosafluorodecane-1-sulfonic"[tw] OR "heneicosafluoro-1-
decanesulfonic"[tw] OR henicosafluorodecanesulphonic[tw] OR "henicosafluorodecane 
sulphonic"[tw] OR "henicosafluorodecane sulfonic"[tw] 
230 
#17 919005-14-4[rn] OR 958445-44-8[rn] OR ADONA[tw] OR "3H-perfluoro-3-[(3-methoxy-





(trifluoromethoxy)propoxy]"[tw] OR "3H-perfluoro-3-[(3-methoxy-propoxy)propanoate]"[tw] 
#18 13252-13-6[rn] OR 62037-80-3[rn] OR 236-236-8[rn] OR 26099-32-1[rn] OR GenX[tw] OR "2-
(Heptafluoropropoxy)-2,3,3,3-tetrafluoro-propionic"[tw] OR "2-(Heptafluoropropoxy)-2,3,3,3-
tetrafluoropropanoic"[tw] OR "2-(Heptafluoropropoxy)-2,3,3,3-tetrafluoropropionic"[tw] OR "2-
(Heptafluoropropoxy)tetrafluoropropionic acid"[nm] OR "2-
(Heptafluoropropoxy)tetrafluoropropionic"[tw] OR "2-
(Heptafluoropropoxy)tetrafluoropropionicacid"[tw] OR "2,3,3,3-tetrafluoro-2-
(heptafluoropropoxy)propanoic acid"[nm] OR "2,3,3,3- tetrafluoro-2-
(heptafluoropropoxy)propanoic acid"[tw] OR "2,3,3,3-tetrafluoro-2- (1,1,2,2,3,3,3-
heptafluoropropoxy)-Propanoic acid"[tw] OR "2,3,3,3-tetrafluoro-2- (1,1,2,2,3,3,3-
heptafluoropropoxy)propanoic acid"[tw] OR "2,3,3,3-Tetrafluoro-2- (heptafluoropropoxy)propionic 
acid"[tw] OR "2,3,3,3-tetrafluoro-2- (perfluoro propoxy) propanoic"[tw] OR "2,3,3,3-tetrafluoro-2- 
(perfluoro propoxy)propanoic"[tw] OR "2,3,3,3-Tetrafluoro-2-(1,1,2,2,3,3,3- 
heptafluoropropoxy)propanoic acid, ammonium salt"[tw] OR "2,3,3,3-tetrafluoro-2-(1,1,2,2,3,3,3-
heptafluoropropoxy) propanoic"[tw] OR "2,3,3,3-tetrafluoro-2-(1,1,2,2,3,3,3-
heptafluoropropoxy)propanoic"[tw] OR "2,3,3,3-tetrafluoro-2-(1,1,2,2,3,3,3-
heptafluoropropoxy)propionic"[tw] OR "2,3,3,3-tetrafluoro-2-(heptafluoropropoxy) propanoic"[tw] 
OR "2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)propanoate"[tw] OR "2,3,3,3-tetrafluoro-2-
(heptafluoropropoxy)propanoic"[tw] OR "2,3,3,3-Tetrafluoro-2-(heptafluoropropoxy)propionic"[tw] 
OR "2,3,3,3-tetrafluoro-2-(perfluoropropoxy) propanoic"[tw] OR "2,3,3,3-tetrafluoro-2-
(perfluoropropoxy)propanoic"[tw] OR "Ammonium 2-(perfluoropropoxy)perfluoropropionate"[tw] 
OR "Ammonium 2,3,3,3- tetrafluoro-2-(heptafluoropropoxy)propanoate"[tw] OR "ammonium 
perfluoro(2-methyl-3-oxahexanoate)"[tw] OR "Ammonium perfluoro(2-methyl-3-oxahexanoic) 
acid"[tw] OR "FRD902"[tw] OR "GenX-H3N"[tw] OR "HFPO-DA"[tw] OR "hexafluoropropylene oxide 
dimer"[tw] OR "Perfluorinated aliphatic carboxylic acid, ammonium salt"[tw] OR "Perfluorinated 
aliphatic carboxylic acid"[tw] OR "perfluoro-2-methyl-3- oxahexanoic acid"[tw] OR "perfluoro-2-
propoxypropanoic acid"[tw] OR "perfluoro-2-propoxypropionic acid"[tw] OR "perfluoro-2-
propoxypropionic"[tw] OR "perfluoro-αpropoxypropionic acid"[tw] OR "Perfluoro(2- methyl-3-
oxahexanoic) acid"[tw] OR "Perfluoro(2-methyl-3-oxahexanoate) "[tw] OR "Perfluoro(2-methyl-3-
oxahexanoic)"[tw] OR "perfluoro2-(propyloxy)propionic acid"[tw] OR "propanoic acid, 2,3,3,3-
tetrafluoro-2- (heptafluoropropoxy)-"[tw] OR "Propanoic acid, 2,3,3,3-tetrafluoro-2-(1,1,2,2,3,3,3-
heptafluoropropoxy)- "[tw] OR "Propanoic acid, 2,3,3,3-tetrafluoro-2-(1,1,2,2,3,3,3-
heptafluoropropoxy)-, ammonium salt"[tw] OR "Propanoic acid, 2,3,3,3-tetrafluoro-2-
(heptafluoropropoxy)-, ammonium salt"[tw] OR "propionic acid, 2,3,3,3-tetrafluoro-2- 
(heptafluoropropoxy)-"[tw] OR "tetrafluoro-2-(1,1,2,2,3,3,3-heptafluoropropoxy)propanoic"[tw] OR 
"tetrafluoro-2-(heptafluoropropoxy)propanoate"[tw] OR "tetrafluoro-2-
(heptafluoropropoxy)propanoic"[tw] OR "Undecafluoro-2-methyl-3-oxahexanoic acid"[tw] OR 
(("2,3,3,3-Tetrafluoro-2- (heptafluoropropoxy)propionic"[tw] OR "2,3,3,3-tetrafluoro-2- 
(1,1,2,2,3,3,3-heptafluoropropoxy)-Propanoic"[tw] OR "Perfluorinated aliphatic carboxylic"[tw] OR 
"Perfluoro(2-methyl-3- oxahexanoic)"[tw] OR "2,3,3,3-tetrafluoro-2-(1,1,2,2,3,3,3- 
heptafluoropropoxy)propanoic"[tw] OR "2,3,3,3-tetrafluoro-2- (heptafluoropropoxy)propanoic"[tw] 
OR "perfluoro-2- (propyloxy)propionic"[tw] OR "perfluoro-2-methyl-3- oxahexanoic"[tw] OR 
"perfluoro-2-propoxypropanoic"[tw] OR "perfluoro-2-propoxypropionic"[tw] OR "perfluoro-
αpropoxypropionic"[tw]) AND (acid[tw] OR acids[tw])) OR (("Undecafluoro-2- methyl-3-
oxahexanoic"[tw] OR "Ammonium perfluoro(2-methyl-3- oxahexanoic)"[tw] OR "2,3,3,3-Tetrafluoro-
2-(1,1,2,2,3,3,3- heptafluoropropoxy)"[tw] OR "Perfluorinated aliphatic carboxylic"[tw]) AND 
(salt[tw] OR salts[tw] OR acid[tw] OR acids[tw])))) OR (((Undecafluoro AND oxahexanoic) OR 
(Ammonium AND perfluoro AND oxahexanoic) OR (Tetrafluoro AND heptafluoropropoxy) OR 
"Perfluorinated aliphatic carboxylic"[tw] OR "Perfluorinated aliphatic carboxylic"[tw]) AND (salt[tw] 
OR salts[tw] OR acid[tw] OR acids[tw])) OR (GenX AND (fluorocarbon*[tw] OR fluorotelomer*[tw] 
OR polyfluoro*[tw] OR perfluoro-*[tw] OR perfluoroa*[tw] OR perfluorob*[tw] OR perfluoroc*[tw] 
OR perfluorod*[tw] OR perfluoroe*[tw] OR perfluoroh*[tw] OR perfluoron*[tw] OR perfluoroo*[tw] 





#19 13252-14-7[rn] OR "HFPO-TA"[tw] OR HFPO[tw] OR (Hexafluoropropylene[tw] AND ("oxides"[MeSH 
Terms] OR oxide*[tw])) OR ("hexafluoropropene"[tw] AND ("oxides"[MeSH Terms] OR oxide*[tw])) 
OR "hexafluoropropylene oxide"[tw] OR "HFPO trimer"[tw] 
62 
#20 73606-19-6[rn] OR "6:2 ClPFESA"[tw] OR "6:2 Cl PFESA"[tw] OR "6:2 chlorinated polyfluorinated 
ether sulfonic acid"[nm] OR "chlorinated polyfluorinated ether sulfonic"[tw] OR "2-[(6-Chloro-
1,1,2,2,3,3,4,4,5,5,6,6-dodecafluorohexyl)oxy]-1,1,2,2-tetrafluoroethanesulfonic"[tw] OR "2-(6-
Chlorododecafluorohexyloxy)-1,1,2,2-tetrafluoroethanesulfonic"[tw] OR "6:2 Cl-PFESA" OR "Cl-
PFESA" OR (Cl[tw] AND (PFESA[tw] OR PFESAs[tw])) OR (((chlorinated[tw] AND polyfluorinated[tw] 
AND ("sulfonic acids"[MeSH Terms] OR ("sulfonic"[tw] AND "acids"[tw]) OR "sulfonic acids"[tw] OR 
("sulfonic"[tw] AND "acid"[tw]) OR "sulfonic acid"[tw])))) OR "2-(6-chloro-1,1,2,2,3,3,4,4,5,5,6,6-
dodecafluorohexoxy)-1,1,2,2-tetrafluoroethanesulfonic"[tw] 
33 
#21 83329-89-9[rn] OR "8:2 Cl:PFESA"[tw] OR "8:2 Cl PFESA"[tw] OR "8:2 Cl-PFESA"[tw] OR "Cl:PFESA" 
OR "Cl PFESA" OR "8:2 chlorinated polyfluorinated ether sulfonic acid"[nm] OR "8:2 chlorinated 
polyfluorinated ether sulfonic acid"[tw] OR "2-[oxyl]-1,1,2,2-tetrafluoro-ethanesulfonicacid"[tw] OR 
"2-[oxyl]-1,1,2,2-tetrafluoro-ethanesulfonic"[tw] OR (chlorinated[tw] AND polyfluorinated[tw] AND 





#22 27619-97-2[rn] OR 59587-39-2[rn] OR "6:2 FTSA"[tw] OR "6:2 FTSA" OR "6:2 FtS"[tw] OR ("6:2"[tw] 
AND FTSA[tw]) OR ("6:2"[tw] AND FtS[tw]) OR "6:2 fluorotelomer sulfonic"[tw] OR "6:2 
fluorotelomer sulphonic"[tw] OR "fluorotelomer sulfonic"[tw] OR "fluorotelomer sulphonic"[tw] OR 
"3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctane-1-sulfonic"[tw] 
48 
#23 39108-34-4[rn] OR 254-295-8[rn] OR "8:2 FTSA" OR "8:2 fluorotelomer sulfonic"[tw] OR "8:2 
fluorotelomer sulphonic"[tw] OR "2-(Perfluorooctyl)ethane-1-sulphonic"[tw] OR "2-
(Perfluorooctyl)ethane-1-sulfonic"[tw] OR ("8:2"[tw] AND fluorotelomer[tw]) OR ("8:2"[tw] AND 
FTSA[tw]) OR ("8:2"[tw] AND FtS[tw]) OR "Heptadecafluorodecanesulphonic"[tw] OR 
"heptadecafluorodecane-1-sulfonic"[tw] OR "Perfluorodecanesulfonic"[tw] OR 
"Heptadecafluorodecane-1-sulphonic"[tw] OR "heptadecafluoro-1-Decanesulfonic"[tw] OR 
"3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecanesulphonic"[tw] OR 
"3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecane-1-sulfonic"[tw] OR "1H,1H,2H,2H-
Perfluorodecanesulphonic acid"[tw] OR "1-Decanesulfonic acid,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
heptadecafluoro-"[tw] 
1917 
#24 2991-50-6[rn] OR NEtFOSAA[tw] OR "2-(N-ethyl-perfluorooctane sulfanamido) acetic acid"[tw] OR 
"2-(N-ethyl-perfluorooctane sulfonamido) acetic acid"[tw] OR "2-(N-ethyl-
perfluorooctanesulfonamido) acetic acid"[tw] OR "2-(N-Ethylperfluorooctanesulfonamido)acetic 
acid"[tw] OR "2-[ethyl(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl)amino]acetic 
acid"[tw] OR "N-(ethyl)-N-(perfluorooctylsulfonyl)-aminoacetic acid"[tw] OR "n-(ethyl)n-
(perfluorooctylsulfonyl)-aminoacetic acid"[tw] OR "N-(Heptadecafluorooctylsulfonyl)-N-
ethylglycine"[tw] OR "N-ethyl perfluorooctanesulfonamidoacetic acid"[tw] OR "N-ethyl-N-
((1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctyl)sulfonyl)-"[tw] OR "N-ethyl-N-
((heptadecafluorooctyl)sulfonyl)-"[tw] OR "N-Ethyl-N-((heptadecafluorooctyl)sulphonyl)glycine"[tw] 
OR "N-ethyl-N-[(heptadecafluorooctyl)sulfonyl]-"[tw] OR "N-ethylperfluorooctane 
sulfonamidoacetic acid"[tw] OR "N-ethylperfluorooctane sulfonamidoacetic"[tw] 
2 
#25 2355-31-9[rn] OR NMeFOSAA[tw] OR "2-(N-Methyl-perfluorooctane sulfanamido) acetic acid"[tw] 
OR "2-(N-methyl-perfluorooctane sulfonamido) acetic acid"[tw] OR "2-(N-




methylglycine"[tw] OR "N-[(heptadecafluorooctyl)sulfonyl]-N-methyl-"[tw] OR "N-
[(heptadecafluorooctyl)sulfonyl]-N-methylglycine"[tw] OR "N-methyl 
perfluorooctanesulfonamidoacetic acid"[tw] OR "N-methylperfluorooctane sulfonamidoacetic 
acid"[tw] 




#27 39492-90-5[rn] OR PFO4DA[tw] OR "1,1,1,3,3,5,5,7,7,9,9-Undecafluoro-2,4,6,8-tetraoxadecan-10-oic 
acid"[tw] OR "3,5,7,9-Tetraoxadecanoicacid, 2,2,4,4,6,6,8,8,10,10,10-undecafluoro-"[tw] OR 
"Perfluoro-3,5,7,9-butaoxadecanoic"[tw] OR "Perfluoro-3,5,7,9-tetraoxadecanoic"[tw] 
1 
#28 39492-91-6[rn] OR PFO5DoDA[tw] OR "1,1,1,3,3,5,5,7,7,9,9,11,11-Tridecafluoro-2,4,6,8,10-




#29 773804-62-9[rn] OR "Hydro-Eve"[tw] OR "Hydro Eve"[tw] OR "HydroEve"[tw] OR "2,2,3,3-
tetrafluoro-3-((1,1,1,2,3,3-hexafluoro-3-(1,2,2,2-tetrafluoroethoxy)propan-2-yl)oxy)propanoic"[tw] 
0 
#30 PFAS*[tiab] OR PFCs[tiab] OR PFAA*[tiab] OR perfluorochemical*[tiab] OR perfluorinated[tiab] OR 
("per-"[tiab] AND polyfluoroalkyl[tiab]) OR "perfluorinated alkyl"[tiab] OR "Perfluorinated 
carboxylic"[tiab] OR "perfluorinated chemicals"[tiab] OR "perfluoroalkyl acid"[tiab] OR 
"perfluoroalkyl acids"[tiab] OR ("perfluoroalkyl sulfonic"[tiab] AND (acid*[tiab] OR acid[tiab] OR 
acids[tiab])) OR ("perfluoroalkyl sulphonic"[tiab] AND (acid*[tiab] OR acid[tiab] OR acids[tiab])) OR 
"perfluoroalkyl sulphonic"[tiab] OR ("poly-"[tiab] AND perfluoroalkyl[tiab]) OR "polyfluorinated 
alkyl"[tiab] OR "polyfluorinated chemicals"[tiab] OR ("polyfluorinated"[tiab] AND substance*[tiab]) 
OR “fluorinated polymer”[tiab] OR “fluorinated polymers”[tiab] OR (fluorinated[tiab] AND 
(polymer[tiab] OR polymers[tiab])) OR (fluorinated[tiab] AND surfactant*[tiab]) OR (fluorinated[tiab] 
AND telomer*[tiab]) OR fluoro-telomer*[tiab] OR (fluorocarbon[tiab] AND (polymer[tiab] OR 
polymers[tiab])) OR Fluoropolymer*[tiab] OR Fluorosurfactant*[tiab] OR fluorotelomer*[tiab] OR 
(Perfluorinated[tiab] AND carboxylic[tiab]) OR (perfluorinated[tiab] AND substance*[tiab]) OR 
perfluoroalkyl[tiab] OR (perfluoroalkyl[tiab] AND acid[tiab]) OR (perfluoroalkyl[tiab] AND acids[tiab]) 
OR (perfluoroalkyl[tiab] AND substance*[tiab]) OR (perfluorocarbon*[tiab] AND (chemical*[tiab] OR 
compound*[tiab])) OR perfluorocarboxylic[tiab] OR perfluorosulfonic[tiab] OR polyfluorinated[tiab] 
OR polyfluoroalkyl[tiab] OR (polyfluoroalkyl[tiab] AND acid[tiab]) OR (polyfluoroalkyl[tiab] AND 
acids[tiab]) OR (polyfluoroalkyl[tiab] AND substance*[tiab]) OR polyflurochemical*[tiab] 
8,948 
#31 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR 
#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 
OR #28 OR #29 OR #30 
12,490 
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